

## PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International BureauB2  
11

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |   |  |
|---|--|---|--|
| (51) International Patent Classification 7 :<br><br>C12N 15/11, 15/63, 15/82, A01N 63/00,<br>A01H 5/00  |  | A1  | (11) International Publication Number: WO 00/68374<br><br>(43) International Publication Date: 16 November 2000 (16.11.00) |
| (21) International Application Number: PCT/EP00/04117<br><br>(22) International Filing Date: 8 May 2000 (08.05.00)  |  | (74) Agent: BECKER, Konrad; Novartis AG, Patent and Trademark<br>Dept. Agribusiness, Site Rosental, CH-4002 Basel (CH).   |  |
| (30) Priority Data:<br>09/309,038 10 May 1999 (10.05.99) US   |  | (81) Designated States: AE, AG, AI, AM, AT, AU, AZ, BA, BB,<br>BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM,<br>DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,<br>IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,<br>LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,<br>RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,<br>UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH,<br>GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian<br>patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European<br>patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,<br>IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,<br>CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |  |
| (71) Applicant (for all designated States except AT/US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).<br><br>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).   |  | Published<br>With international search report.<br>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.  |  |
| (72) Inventors; and<br><br>(75) Inventors/Applicants (for US only): HEIFETZ, Peter, Bernard [US/US]; 3916 Sturbridge Drive, Durham, NC 27713 (US). PATTON, David, Andrew [US/US]; 3506 Long Ridge Road, Durham, NC 27703 (US). LEVIN, Joshua, Zvi [US/US]; 1008 Urban Avenue, Durham, NC 27701 (US). QUE, Quideng [CN/US]; 108 Forest Brook Drive, Apex, NC 27502 (US). DE HAAN, Petrus, Theodorus [NL/NL]; Kruideel 34, NL-1602 GI Enkhuizen (NL). GIELEN, Johannes, Jacobus, Ludgerus [NL/FR]; 6A, impasse Manet, F-31340 Aucanville (FR).            |  |   |  |
| (54) Title: REGULATION OF VIRAL GENE EXPRESSION   |  |   |  |
| (57) Abstract   |  |   |  |
| <p>The present invention relates to methods to alter the expression of a viral gene in a cell using sense and antisense RNA fragments of the gene. The sense and antisense RNA fragments are capable of pairing and forming a double-stranded RNA molecule, thereby altering the expression of the gene. The present invention also relates to cells, plants or animals, their progeny and seeds derived thereof, obtained using a method of the present invention. Preferably, such cells, plants or animals are resistant or tolerant to viruses.</p> |  |   |  |

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

|    |                          |    |                                       |    |   |    |                          |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania                  | ES | Spain                                 | LS | Lesotho                                   | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                               | LT | Lithuania                                 | SK | Slovakia                 |
| AT | Austria                  | FR | France                                | LU | Luxembourg                                | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                 | LV | Latvia                                    | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                        | MC | Monaco                                    | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                               | MD | Republic of Moldova                       | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                 | MG | Madagascar                                | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                | ML | Mali                                      | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                               | MN | Mongolia                                  | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                               | MR | Mauritania                                | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                | MW | Malawi                                    | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                               | MX | Mexico                                    | US | United States of America |
| CA | Canada                   | IT | Italy                                 | NE | Niger                                     | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                 | NL | Netherlands                               | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                 | NO | Norway                                    | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                            | NZ | New Zealand                               | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's Republic of Korea | PL | Poland                                    |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                     | PT | Portugal                                  |    |                          |
| CN | China                    | KZ | Kazakhstan                            | RO | Romania                                   |    |                          |
| CU | Cuba                     | LC | Saint Lucia                           | RU | Russian Federation                        |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                         | SD | Sudan                                     |    |                          |
| DE | Germany                  | LK | Sri Lanka                             | SE | Sweden                                    |    |                          |
| DK | Denmark                  | LR | Liberia                               | SG | Singapore                                 |    |                          |
| EE | Estonia                  |    |                                       |    |   |    |                          |

## REGULATION OF VIRAL GENE EXPRESSION

The present invention relates to methods of altering the expression of viral genes in cells, plants or animals using sense and antisense RNA fragments of said genes, and to cells, plants or animals with altered viral gene expression obtained using the methods of the present invention. The invention particularly relates to such cells, plants or animals resistant or tolerant to viruses.

An area of deep interest is resistance or tolerance to viruses. Viruses affect most living organisms. In crops, large proportions of the harvest may be lost due to virus infections. Farm animals are also often infected by viruses and must sometimes be slaughtered to prevent spreading of the disease leading to dramatic economic consequences. Companion animals are also affected by viruses, and, finally, viruses infect humans causing a lot of suffering. Although treatments against viruses have been developed, they are very often either extremely expensive or of limited efficiency.

It is desirable to modify cells, plants or animals so that the expression of a particular viral gene is altered to create cells, plants or animals resistant or tolerant to said virus. Current methods to alter the expression of a gene usually rely upon techniques of sense or antisense suppression. Unfortunately, these methods are often variable and unpredictable in their ability to alter gene expression, and in many cases a complete disruption of the particular gene activity is not achieved.

There is therefore a long-felt but unfulfilled need for novel methods and compositions allowing one to effectively and predictably alter the expression of a viral gene to obtain cells, plants or animals with resistance or tolerance to viruses.

The present invention relates to methods of altering the expression of a viral gene in cells, plants or animals using sense and antisense RNA fragments of the gene. Importantly, such sense and antisense RNA fragments are capable of forming a double-stranded RNA molecule. Particularly, the present invention relates to methods and compositions of conferring upon a cell, plant or animal resistance or tolerance to viruses. Preferably the invention relates to methods of conferring upon a plant resistance or tolerance to viruses. The invention also preferably relates to plant cells obtained using such methods, to plants derived from such cells, to the progeny of such plants and to seeds derived from such plants. In such plant cells or plants, the alteration of the gene expression of a particular viral

gene is more effective, selective and more predictable than the alteration of the gene expression of a particular viral gene obtained using current methods known in the art.

The invention therefore provides:

A method comprising introducing into a cell a plurality of sub-sequences, e.g. RNA fragments or DNA sequences, characterized in that at least two of the sub-sequences have sense and antisense sequences of viral RNAs and are capable of forming a double-stranded RNA molecule. Preferably, the method comprises introducing into a cell an RNA which consists of a plurality of sub-sequences characterized in that at least two of the sub-sequences have the sequences of viral RNAs. Preferably, the RNA contains at least one translational stop codon located upstream of the 3' terminal sub-sequence. In another preferred embodiment, the method comprises introducing into a cell a nucleotide sequence or DNA molecule encoding expression of said RNA.

The invention therefore provides:

A method comprising introducing into a cell a sense RNA fragment of a viral target gene and an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said target gene in said cell is altered. In a preferred embodiment, the target gene comprises a viral genome or a portion thereof and the cell is preferably resistant or tolerant to viruses. In a preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the RNA fragments comprise nucleotide sequences derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In a further preferred embodiment, a cell is a plant cell, such as a monocotyledonous or a dicotyledonous cell. In another preferred embodiment, the RNA fragments are comprised in two different RNA molecules. In another preferred embodiment, the RNA fragments are mixed before being introduced into said cell. In another preferred embodiment, the RNA fragments are mixed before being introduced into said cell under conditions allowing them to form a double-stranded RNA molecule. In another preferred embodiment, the RNA fragments are introduced into said cell sequentially. In yet another preferred embodiment, the RNA fragments are comprised in

one RNA molecule. In such case, the RNA molecule is preferably capable of folding such that said RNA fragments comprised therein form a double-stranded RNA molecule.

The invention further provides:

A method comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of a viral target gene, and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said viral target gene in said cell is altered. In a preferred embodiment, the target gene comprises a viral genome or a portion thereof and the cell is preferably resistant or tolerant to viruses. In a preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In a further preferred embodiment, a cell is a plant cell, such as a monocotyledonous or a dicotyledonous cell. In a preferred embodiment, the DNA sequences are stably integrated in the genome of the plant cell. In a preferred embodiment, the DNA molecule further comprises a promoter operably linked to said first or said second DNA sequence. In another preferred embodiment, the first DNA sequence and the second DNA sequence are comprised in two different, i.e. separate DNA molecules.

Alternatively, the first DNA sequence and the second DNA sequence are comprised in one DNA molecule. In this case, the first DNA sequence and the second DNA sequence are preferably comprised in the same DNA strand of said DNA molecule meaning that the sense RNA fragment and the antisense RNA fragment are comprised in one RNA molecule. Preferably, the RNA molecule is capable of folding such that said RNA fragments comprised therein form a double-stranded region. Examples of such RNA molecules comprise the inverted repeat sequence of SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25 or SEQ ID NO: 28. In another preferred embodiment, the sense RNA fragment and the antisense RNA fragment are comprised in or expressed as two RNA molecules. In this case, the first DNA sequence and the second DNA sequence are preferably operably linked to a bi-directional promoter or, alternatively, the first DNA

sequence is operably linked to a first promoter and the second DNA sequence is operably linked to a second promoter, wherein the first promoter and the second promoter are the same promoter or different promoters. In another preferred embodiment, the first DNA sequence and the second DNA sequence are comprised in complementary strands of said DNA molecule.

In yet another preferred embodiment, the first DNA sequence is the complementary DNA strand of the second DNA sequence in said DNA molecule. In this case, the DNA molecule further comprises a first promoter operably linked to said first or second DNA sequence. In a preferred embodiment, the DNA molecule further comprises a first site-specific recombination site between said first promoter and said first or second DNA sequence and a second site-specific recombination site at the 3'-end of said first DNA sequence, wherein said first and second site-specific recombination sites are capable of inverting said first or second DNA sequence between said first and second site-specific recombination sites in presence of a site-specific recombinase. In a further preferred embodiment and as a result of said inverting said first promoter is capable of expressing said second (or first, depending on which DNA sequence was originally linked to the promoter) DNA sequence. The plant cell preferably further comprises a site-specific recombinase capable of recognizing said site-specific recombination sites.

In yet another preferred embodiment, the DNA molecule further comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence, wherein the first promoter and the second promoter comprise the same promoter or comprise different promoters.

In another preferred embodiment, the promoter in the DNA molecule comprises a native promoter of said cell. In a further preferred embodiment, the promoter is a heterologous promoter, for example a tissue specific promoter, a developmentally regulated promoter, a constitutive promoter or an inducible promoter. Optionally, the promoter is a divergent or bi-directional promoter capable of initiating transcription of DNA sequences on each side of the promoter.

In yet another preferred embodiment, the DNA sequence further comprises a linker between the DNA sequences encoding the sense and antisense RNA fragments. The linker comprises, e.g. an expression cassette comprising a functional gene, e.g. a selectable marker gene or regulatory sequences, e.g. intron processing signals.

The invention also further provides:

A cell comprising the sense and antisense RNA fragments of the present invention, wherein the expression of said viral target gene in said cell is altered by said RNA fragments. In a preferred embodiment, the cell is resistant or tolerant to viruses. In a preferred embodiment, the cell is a plant cell and the invention further provides a plant and the progeny thereof derived from the plant cell, and seeds derived from the plant.

The invention also provides:

DNA constructs comprising the DNA sequences of the present invention.

In a preferred embodiment, such a DNA construct comprises a first DNA sequence capable of expressing in a cell a sense RNA fragment of a viral genome or portion thereof and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome or portion thereof, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule. In another preferred embodiment, the expression of said viral genome or portion thereof in said cell is altered. In another preferred embodiment, the cell is a plant cell. In another preferred embodiment, the virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses. In another preferred embodiment, the DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, a movement protein gene or portions thereof. In yet another preferred embodiment, the DNA construct further comprises a promoter operably linked to said first or said second DNA sequence. In yet another preferred embodiment, the DNA construct comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence. In yet another preferred embodiment, the DNA construct further comprises a bi-directional promoter operably linked to said first DNA sequence and said second DNA sequence.

The invention further provides:

A DNA construct comprising:

(a) a first DNA sequence capable of expressing in a cell a sense RNA fragment of a target gene and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein said first DNA

sequence is the complementary strands of said second DNA sequence in said DNA construct,

(b) a promoter operably linked to said first or second DNA sequence,

(c) a first site-specific recombination site between said promoter and said first or second DNA sequence, and

(d) a second site-specific recombination site at the 3'-end of said first or second DNA sequence, wherein said first and second site-specific recombination sites are capable of inverting said first or second DNA sequence between said first and second site-specific recombination sites in presence of a site-specific recombinase.

- In a preferred embodiment, the expression of said target gene in said cell is altered.

The invention further provides:

A DNA construct comprising:

(a) a first DNA sequence capable of expressing in a cell a sense RNA fragment of a target gene and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein said first DNA sequence is the complementary strands of said second DNA sequence in said DNA construct,

(b) a first promoter operably linked to said first DNA sequence,

(c) a second promoter operably linked to said second DNA sequence.

In a preferred embodiment, the expression of said target gene in said cell is altered.

A "double-stranded RNA (dsRNA)" molecule comprises a sense RNA fragment of a target gene and an antisense RNA fragment of the same target gene, which both comprise nucleotide sequences complementary to one another, thereby allowing the sense and antisense RNA fragments to pair and form a double-stranded RNA molecule.

"Complementary" refers to two nucleotide sequences which comprise antiparallel nucleotide sequences capable of pairing with one another upon formation of hydrogen bonds between the complementary base residues in the antiparallel nucleotide sequences.

"Antiparallel" refers herein to two nucleotide sequences paired through hydrogen bonds between complementary base residues with phosphodiester bonds running in the 5'-3' direction in one nucleotide sequence and in the 3'-5' direction in the other nucleotide sequence.

A "target gene" is any viral gene of known function or is a gene whose function is unknown, but whose total or partial nucleotide sequence is known. A target gene is an native gene of the cell or is a heterologous gene which had previously been introduced into the cell, preferably by genetic transformation or viral infection of the cell. Preferably, the target gene is a gene in a plant cell.

A "native" gene refers to a gene which is present in the genome of the untransformed cell.

An "essential" gene is a gene encoding a protein such as e.g. a biosynthetic enzyme, receptor, signal transduction protein, structural gene product, or transport protein that is essential to the growth or survival of the cell.

To "alter" the expression of a target gene in a cell means that the level of expression of the target gene in a cell after applying the method of the present invention is different from its expression in the cell without applying the method. To alter gene expression preferably means that the expression of the target gene in the cell is reduced, preferably strongly reduced, more preferably the expression of the gene is not detectable, resulting in a knockout mutant phenotype in cells or plants or animals derived thereof.

"Isolated" is, in the context of the present invention, an isolated nucleic acid molecule that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell.

"Expression cassette" as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region usually codes for a protein of interest but may

also code for a functional RNA of interest, for example antisense RNA or a nontranslated RNA, in the sense or antisense direction. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular DNA sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue or organ or stage of development.

"Heterologous" as used herein means "of different natural origin" or represents a non-natural state. For example, if a host cell is transformed with a nucleic acid sequence derived from another organism, particularly from another species, that nucleic acid sequence is heterologous with respect to that host cell and also with respect to descendants of the host cell which carry that nucleic acid sequence. Similarly, heterologous refers to a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, e.g. a different copy number, or under the control of different regulatory elements.

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence (number of complementary bases in the complementary sequence divided by total number of bases in the complementary sequence) desirably is at least 80%, more

desirably 85%, preferably at least 90%, more preferably at least 95%, still more preferably at least 99%.

"Regulatory elements" refer to sequences involved in conferring the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.

A "plant" refers to any plant or part of a plant at any stage of development. Therein are also included cuttings, cell or tissue cultures and seeds. As used in conjunction with the present invention, the term "plant tissue" includes, but is not limited to, whole plants, plant cells, plant organs, plant seeds, protoplasts, callus, cell cultures, and any groups of plant cells organized into structural and/or functional units.

"Virus resistance or tolerance" means herein that a resistant or tolerant cell, plant or animal is either not susceptible or has reduced susceptibility to one or more viruses as compared to a sensitive cell, plant or animal. Resistance or tolerance for instance means that the usual symptoms of a virus infection are absent or reduced, or that accumulation or replication of the virus in the cell is prevented or reduced, or that movement of the virus, e.g. from cell to cell is prevented or reduced.

By "alteration of the expression of the viral genome or of a portion thereof" is typically understood that accumulation, replication or movement of the virus or a portion or component thereof, e.g. a RNA, DNA or protein of the virus, in the cell is affected.

The present invention relates to methods to regulate, i.e. alter the expression of a viral gene in cells, plants or animals. Commonly available methods to regulate the expression of a gene in cells, plants or animals lack predictability and show variability depending upon which gene is to be regulated. The present method alleviates these problems and provides for reproducible and efficacious regulation of a gene in cells, plants or animals.

The gene the expression of which is regulated is a viral genome or a portion thereof. In a preferred embodiment, a cell is an eukaryotic cell, more preferably a plant cell, such as a

monocotyledonous or a dicotyledonous cell, or an animal cell e.g. from a mammal, e.g. a human, a bovine, an ovine, a porcine, a feline or a canine, or from an avian.

The present invention utilizes a sense RNA fragment and an antisense RNA fragment of a viral target gene to alter the expression of the gene in a cell. In a first embodiment, the invention provides a method comprising introducing into a cell a sense RNA fragment of a target gene and an antisense RNA fragment of said target gene, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule, wherein the expression of said target gene in said cell is altered. The RNA fragments are introduced in the cells by different transformation methods such as particle

- bombardment or PEG-mediated transformation or electroporation. In another preferred embodiment, other techniques, such as microinjection of the RNA fragments, are used. In a preferred embodiment, the RNA fragments are comprised in two different RNA molecules. In this case, the RNA fragments are mixed before being introduced into said cell, e.g. under conditions allowing them to form a double-stranded RNA molecule. In another preferred embodiment, the RNA fragments are introduced into said cell sequentially.

Preferably, the time interval between the introduction of each of the RNA molecules is short, preferably less than one hour. In yet another embodiment, the RNA fragments are comprised in one RNA molecule. By using one single RNA molecule the two complementary RNA fragments are in close proximity such that pairing and is favored. In such case, the RNA molecule is preferably capable of folding such that said RNA fragments comprised therein form a double-stranded region. In this case, the complementary parts of the RNA fragments recognize one another, pair with each other and form the double-stranded RNA molecule. In a preferred embodiment, the RNA fragments are incubated under conditions allowing them to form a double-stranded RNA molecule prior to introduction into the cell. In yet another embodiment, the RNA molecule comprises a linker between the sense RNA fragment and the antisense RNA fragment. The linker preferably comprises a RNA sequence encoded by an expression cassette comprising a functional gene, e.g. a selectable marker gene. In another embodiment, the linker comprises a RNA sequence encoded by regulatory sequences, which e.g. comprise intron processing signals.

In a further embodiment, the present invention provides a method of altering the expression of a viral genome comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable

of forming a double-stranded RNA molecule. In a preferred embodiment, the first DNA sequence and the second DNA sequence are stably integrated in the genome of the cell. In another preferred embodiment, the DNA sequences are comprised in two different DNA molecules. In another preferred embodiment, the DNA sequences are comprised in one DNA molecule. In such case, the DNA molecule preferably encodes a single RNA molecule which comprises the sense and antisense RNA fragments. By using one single RNA molecule the two complementary RNA fragments are in close proximity such that pairing and is favored. The DNA molecule encodes two separate RNA molecules, e.g. one RNA molecule comprising a sense RNA fragment and one RNA molecule comprising an antisense RNA fragment. The single RNA molecule or the two distinct RNA molecules are preferably capable of folding such that said RNA fragments comprised therein form a double-stranded region, in which the complementary parts of the RNA fragments recognize one another, pair with each other and form the double-stranded RNA molecule.

In one embodiment, the single DNA molecule or each of the two distinct DNA molecules comprises a promoter operably linked to said DNA sequences. In a preferred embodiment, the promoter in the DNA sequence comprises a native plant promoter or the natural promoter of said viral gene to be inactivated, in order to insure that the double-stranded RNA is expressed in the same tissues and at the same time in development as the viral target gene. In another embodiment the promoter is a heterologous promoter, for example a tissue specific promoter, a developmentally regulated promoter, a constitutive promoter or an inducible promoter.

In yet another embodiment, the DNA sequence comprises a linker between the DNA sequences encoding said two complementary RNA fragments. The linker preferably comprises an expression cassette comprising a functional gene, e.g. a selectable marker gene. In another embodiment, the linker comprises regulatory sequences, which e.g. comprise intron processing signals.

DNA molecules of the present invention are transformed into cells using methods well-known in the art or described below. The present invention also provides a DNA construct comprising DNA sequences of the present invention, a recombinant vector comprising such DNA constructs and a composition comprising DNA sequences of the present invention. In the present invention the complementary region between the sense and antisense RNA fragments is desirably at least 15 nucleotides long, more desirably at least 50 nucleotides long, and preferably at least 500 bp long. Preferably, the complementary region is less than 5 kb and more preferably less than 2 kb. In one particular embodiment the complementary

region between the sense and antisense RNA fragments comprises the coding region of the target gene. In another preferred embodiment, the complementary region comprises untranslated regions (UTR) of the target gene, e.g. 5' UTR or 3' UTR. In yet another preferred embodiment, a DNA sequence encoding a sense or antisense RNA fragment of the present invention is derived from a c-DNA molecule or comprises regulatory elements of the viral target gene whose expression is to be altered, such as promoter or termination signals.

In another preferred embodiment, the complementary region between the sense and antisense RNA fragments is identical to the corresponding sequence of the gene whose expression is altered. In another preferred embodiment, the complementary region between the sense and antisense RNA fragments is substantially similar to the corresponding sequence of the gene whose expression is altered and is still capable of altering the expression of the gene. In this case, the complementary region is desirably at least 50% identical to the corresponding sequence of the gene whose expression is altered more desirably at least 70% identical, preferably at least 90% identical, more preferably at least 95% identical. Thereby, using a single double-stranded RNA molecule allows to alter the expression of a single gene or of a plurality of genes, the single gene comprising sequences identical to the double-stranded RNA or being substantially similar to the double-stranded RNA.

In another preferred embodiment, the complementary region between the sense and antisense RNA fragments does not contain any mismatch between the sense and antisense RNA fragments. In another preferred embodiment, the complementary region between the sense and antisense RNA fragments comprises at least one mismatch between the sense and antisense RNA fragments, and the two RNA fragments are still capable of pairing and forming a double-stranded RNA molecule, thereby altering the expression of the gene.

Desirably, there is less than 50% mismatch between the sense and antisense RNA fragments in the complementary region, more desirably less than 30% mismatch, preferably less than 20% mismatch, more preferably less than 10% mismatch, yet more preferably less than 5 % mismatch.

#### Resistance or Tolerance to Viruses

The present invention results in cells, animals or plants which are virus resistant or tolerant. Viruses controlled using the present invention comprise but are not limited to dsDNA viruses, dsRNA viruses, plus-strand and minus-strand ssRNA viruses, ambisense RNA

viruses and retroviruses. Preferably controlled are plant viruses, such astroviruses (e.g. tomato spotted wilt virus abbreviated TSWV), potyviruses (e.g. turnip mosaic virus abbreviated TuMV, lettuce mosaic virus abbreviated LMV, water melon mosaic virus II abbreviated WMVII, Zucchini yellow mosaic virus abbreviated ZYMV, potato virus Y abbreviated PVY, and papaya ringspot virus abbreviated PRSV), potexviruses, tobamoviruses (e.g. pepper mild mottle virus abbreviated PMMV, and tomato mosaic virus abbreviate ToMV), luteoviruses (e.g. beet western yellows virus abbreviated BWYV, and beet mild yellowing virus abbreviated BMYV), cucumoviruses (e.g. cucumber mosaic virus abbreviated CMV), geminiviruses (e.g. tomato yellow leafcurl virus abbreviated TYLCV), caulimoviruses (e.g. Cauliflower mosaic virus abbreviated CaMV), bromoviruses, closteroviruses, tombusviruses and furoviruses (e.g. beet necrotic yellow vein virus abbreviated BNYVV). Additional classes of viruses which can be controlled using the present invention are described in Zacomer et al. (1995) Journal of General Virology, 76: 231-247 and in Martelli (1992) Plant Disease, 76: 436-441. Preferred DNA sequences of a viral genome to achieve virus control correspond to regions of the genes encoding viral coat proteins, viral nucleocapsid proteins, viral replicases, movement proteins and the like. Further nucleotide sequences useful to control virus genome expression are described in WO 95/09920. Preferred DNA sequences may include portions of the viral genome not translated into proteins, e.g. 5' or 3' untranslated regions.

Preferably, a method of the present invention leads to resistance or tolerance to a broad-spectrum of viruses. For example, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other viruses in the same virus class, group or genus. Alternatively, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other isolates of the same virus. Also, a method of the present invention leads to resistance or tolerance to the virus encoded by the viral genome and other viruses in the same virus group or genus in different species, preferably in related species, preferably species in which such viruses exist. Optionally, more than one pair, i.e. at least two pairs of sense and antisense RNA fragments which are capable of forming a dsRNA are used. Such pairs are for example derived from the same viral genome, but from different portions of the same viral genome. Alternatively, such pairs are derived from different viral genomes. Thus, resistance or tolerance to different virus classes, groups or genera is achieved using the present invention.

Plant cells and plants derived thereof, which are virus resistant or tolerant are preferably dicotyledonous plants. Methods to confer resistance or tolerance to furoviruses (see e.g. Rush and Heidel (1995) Plant Disease 79: 868-875) in sugar beet and canola are disclosed in the present invention and described in further detail for BNYVV, the causal agent of rhizomania (crazy roots) in sugar-beet, in Example 9. Methods to confer resistance or tolerance to "virus yellow" (see e.g. CRC Handbook on Disease of Sugar Beet, Volume II, pp. 35-52) such as BMYV and beet western yellows virus (BWYVV) that infect sugar beet and oilseed rape, respectively, are described in further detail in Example 8.

Methods of the present invention also confer tolerance or resistance to viruses in

- monocotyledonous plants. For example, using the teachings of the present invention and of US patent 5,569,828 tolerance or resistance to Maize chlorotic dwarf virus is obtained. Similarly, using the teachings of the present invention and of US patent 5,428,144 tolerance or resistance to Maize dwarf mosaic virus is achieved.

#### Plant Transformation Technology

DNA molecules of the present invention are incorporated in plant or bacterial cells using conventional recombinant DNA technology. Generally, a DNA molecule of the present invention is comprised in a transformation vector. A large number of such vector systems known in the art are used, such as plasmids, bacteriophage viruses and other modified viruses. The components of the expression system are also modified, e.g. to increase expression of the sense and antisense RNA fragments. For example, truncated sequences, nucleotide substitutions or other modifications are employed. Expression systems known in the art are used to transform virtually any crop plant cell under suitable conditions. A transgene comprising a DNA molecule of the present invention is preferably stably transformed and integrated into the genome of the host cells. In another preferred embodiment, the transgene comprising a DNA molecule of the present invention is located on a self-replicating vector. Examples of self-replicating vectors are viruses, in particular gemini viruses. Transformed cells are preferably regenerated into whole plants.

Plants transformed in accordance with the present invention may be monocots or dicots and include, but are not limited to, maize, wheat, barley, rye, sweet potato, bean, pea, chicory, lettuce, cabbage, cauliflower, broccoli, turnip, radish, spinach, asparagus, onion, garlic, pepper, celery, squash, pumpkin, hemp, zucchini, apple, pear, quince, melon, plum, cherry, peach, nectarine, apricot, strawberry, grape, raspberry, blackberry, pineapple, avocado, papaya, mango, banana, soybean, tomato, sorghum, sugarcane, sugarbeet, sunflower,

rapeseed, clover, tobacco, carrot, cotton, alfalfa, rice, potato, eggplant, cucumber, *Arabidopsis*, and woody plants such as coniferous and deciduous trees. Once a desired nucleotide sequence has been transformed into a particular plant species, it may be propagated in that species or moved into other varieties of the same species, particularly including commercial varieties, using traditional breeding techniques.

#### A. Requirements for Construction of Plant Expression Cassettes

Gene sequences intended for expression in transgenic plants are first assembled in expression cassettes behind a suitable promoter expressible in plants. The expression cassettes may also comprise any further sequences required or selected for the expression of the transgene. Such sequences include e.g., but are not restricted to, transcription terminators, extraneous sequences to enhance expression such as introns, vital sequences, and sequences intended for the targeting of the gene product to specific organelles and cell compartments. These expression cassettes can then be easily transferred to the plant transformation vectors described *infra*. The following is a description of various components of typical expression cassettes.

##### 1. Promoters

The selection of the promoter used in expression cassettes determine the spatial and temporal expression pattern of the transgene in the transgenic plant. Selected promoters express transgenes in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and the selection reflects the desired location of accumulation of the gene product. Alternatively, the selected promoter drives expression of the gene under various inducing conditions. Promoters vary in their strength, i.e., ability to promote transcription. Depending upon the host cell system utilized, any one of a number of suitable promoters known in the art is used. For example, for constitutive expression, the CaMV 35S promoter, the rice actin promoter, or the ubiquitin promoter are used. For example, for regulatable expression, the chemically inducible PR-1 promoter from tobacco or *Arabidopsis* is used (see, e.g., U.S. Patent No. 5,689,044).

A preferred category of promoters is that which is wound inducible. Numerous promoters have been described which are expressed at wound sites. Preferred promoters of this kind include those described by Stanford *et al.* Mol. Gen. Genet. 215: 200-208 (1989), Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989),

Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek *et al.* Plant Molec. Biol. 22: 129-142 (1993), and Warner *et al.* Plant J. 3: 191-201 (1993).

Preferred tissue specific expression patterns include green tissue specific, root specific, stem specific, and flower specific. Promoters suitable for expression in green tissue include many which regulate genes involved in photosynthesis, and many of these have been cloned from both monocotyledons and dicotyledons. A preferred promoter is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, Plant Molec. Biol. 12: 579-589 (1989)). A preferred promoter for root specific expression is that described by de Framond (FEBS 290: 103-106 (1991); EP 0 452 269 and a further - preferred root-specific promoter is that from the T-1 gene provided by this invention. A preferred stem specific promoter is that described in US patent 5,625,136 and which drives expression of the maize *trpA* gene.

Preferred embodiments of the invention are transgenic plants expressing nucleotide sequence in a root-specific fashion. Further preferred embodiments are transgenic plants expressing the nucleotide sequence in a wound-inducible or pathogen infection-inducible manner.

## 2. Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription beyond the transgene and its correct polyadenylation. Appropriate transcriptional terminators are those that are known to function in plants and include the CaMV 35S terminator, the *tm1* terminator, the nopaline synthase terminator and the pea *rbcS* E9 terminator. These are used in both monocotyledonous and dicotyledonous plants.

## 3. Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the genes of this invention to increase their expression in transgenic plants. For example, various intron sequences such as introns of the maize *Adh1* gene have been shown to enhance expression, particularly in monocotyledonous cells. In addition, a number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells.

#### 4. Coding Sequence Optimization

The coding sequence of the selected gene may be genetically engineered by altering the coding sequence for optimal expression in the crop species of interest. Methods for modifying coding sequences to achieve optimal expression in a particular crop species are well known (see, e.g. Perlak *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 3324 (1991); and Koziel *et al.*, *Bio/technol.* 11: 194 (1993)).

In another preferred embodiment, a DNA molecule of the present invention is directly transformed into the plastid genome. Plastid transformation technology is extensively described in U.S. Patent Nos. 5,451,513, 5,545,817, and 5,545,818, in PCT application no. WO 95/16783, and in McBride *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 7301-7305. The basic technique for chloroplast transformation involves introducing regions of cloned plastid DNA flanking a selectable marker together with the gene of interest into a suitable target tissue, e.g., using biolistics or protoplast transformation (e.g., calcium chloride or PEG mediated transformation). The 1 to 1.5 kb flanking regions, termed targeting sequences, facilitate homologous recombination with the plastid genome and thus allow the replacement or modification of specific regions of the plastome. Initially, point mutations in the chloroplast 16S rRNA and rps12 genes conferring resistance to spectinomycin and/or streptomycin are utilized as selectable markers for transformation (Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8526-8530; Staub, J. M., and Maliga, P. (1992) *Plant Cell* 4, 39-45). The presence of cloning sites between these markers allowed creation of a plastid targeting vector for introduction of foreign DNA molecules (Staub, J.M., and Maliga, P. (1993) *EMBO J.* 12, 601-606). Substantial increases in transformation frequency are obtained by replacement of the recessive rRNA or r-protein antibiotic resistance genes with a dominant selectable marker, the bacterial *aadA* gene encoding the spectinomycin-detoxifying enzyme aminoglycoside-3'-adenyltransferase (Svab, Z., and Maliga, P. (1993) *Proc. Natl. Acad. Sci. USA* 90, 913-917). Previously, this marker had been used successfully for high-frequency transformation of the plastid genome of the green alga *Chlamydomonas reinhardtii* (Goldschmidt-Clermont, M. (1991) *Nucl. Acids Res.* 19: 4083-4089). Other selectable markers useful for plastid transformation are known in the art and encompassed within the scope of the invention.

Plastid expression, in which genes are inserted by homologous recombination into the several thousand copies of the circular plastid genome present in each plant cell. In a preferred embodiment, a DNA of the present invention is inserted into a plastid targeting vector and transformed into the plastid genome of a desired plant host. Plants homoplasmic

for plastid genomes containing the DNA molecule of the present invention are obtained, and are preferentially capable of high expression of the DNA molecule. Preferably, sense and antisense RNA fragments encoded by the DNA molecule are capable of pairing and of forming a double-stranded RNA molecules in plant plastids to alter the expression of plastid genes. In a preferred embodiment, the sense and antisense fragments do not comprise any mismatch in the complementary region. In another preferred embodiment, the sense and antisense fragments comprise at least one mismatch in the complementary region. In this case, the DNA sequences in the DNA molecule encoding the RNA fragments are not capable of recombining with each other.

#### B. Construction of Plant Transformation Vectors

Numerous transformation vectors available for plant transformation are known to those of ordinary skill in the plant transformation arts, and the genes pertinent to this invention can be used in conjunction with any such vectors. The selection of vector depends upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers are preferred. Selection markers used routinely in transformation include the *nptII* gene, which confers resistance to kanamycin and related antibiotics (Messing & Vierra. Gene 19: 259-268 (1982); Bevan et al., Nature 304:184-187 (1983)), the *bar* gene, which confers resistance to the herbicide phosphinothricin (White et al., Nucl. Acids Res 18: 1062 (1990), Spencer et al. Theor. Appl. Genet 79: 625-631 (1990)), the *hph* gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggemann, Mol Cell Biol 4: 2929-2931), and the *dhfr* gene, which confers resistance to methotrexate (Bourouis et al., EMBO J. 2(7): 1099-1104 (1983)), and the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642).

##### 1. Vectors Suitable for *Agrobacterium* Transformation

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, Nucl. Acids Res. (1984)) and pXYZ. Typical vectors suitable for *Agrobacterium* transformation include the binary vectors pCIB200 and pCIB2001, as well as the binary vector pCIB10 and hygromycin selection derivatives thereof. (See, for example, U.S. Patent No. 5,639,949).

## 2. Vectors Suitable for non-*Agrobacterium* Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences are utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques that do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (e.g. PEG and electroporation) and microinjection. The choice of vector depends largely on the preferred selection for the species being transformed. Typical vectors suitable for non-*Agrobacterium* transformation include pCIB3064, pSOG19, and pSOG35. (See, for example, U.S. Patent No. 5,639,949).

## C. Transformation Techniques

Once the DNA sequence of interest is cloned into an expression system, it is transformed into a plant cell. Methods for transformation and regeneration of plants are well known in the art. For example, Ti plasmid vectors have been utilized for the delivery of foreign DNA, as well as direct DNA uptake, liposomes, electroporation, micro-injection, and microprojectiles. In addition, bacteria from the genus *Agrobacterium* can be utilized to transform plant cells.

Transformation techniques for dicotyledons are well known in the art and include *Agrobacterium*-based techniques and techniques that do not require *Agrobacterium*. Non-*Agrobacterium* techniques involve the uptake of exogenous genetic material directly by protoplasts or cells. This is accomplished by PEG or electroporation mediated uptake, particle bombardment-mediated delivery, or microinjection. In each case the transformed cells are regenerated to whole plants using standard techniques known in the art.

Transformation of most monocotyledon species has now also become routine. Preferred techniques include direct gene transfer into protoplasts using PEG or electroporation techniques, particle bombardment into callus tissue, as well as *Agrobacterium*-mediated transformation.

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

## EXAMPLES

Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Sambrook, et al., Molecular Cloning, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F.M. et al., Current Protocols in Molecular Biology, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987).

- Example 1: **Regulation of the Expression of a Luciferase Gene**

Construction of a chimeric DNA molecule encoding a luciferase RNA duplex

A 738 bp "sense" oriented fragment of the firefly luciferase gene from plasmid pLuc+ (Promega) is amplified from pH108 plasmid DNA using oligonucleotide primers ds\_Luc1 (5' -CGC GGA TCC TGG AAG ACG CCA AAA ACA-3', SEQ ID NO:1; *BamH*I restriction site underlined) and ds\_Luc2 (5' -CGG AAG CTT AGG CTC GCC TAA TCG CAG TAT CCG GAA TG-3', SEQ ID NO:2; *Hind*III restriction site underlined). TurboPfu thermostable DNA polymerase (Stratagene) is used in 50 ul reactions according to the manufacturers protocol with five cycles of 95°C / 1 min, 55°C / 1.5 min, 72°C / 2 min followed by twenty five cycles of 95°C / 1 min, 72°C / 3.5 min. In a similar manner a 737 bp "antisense" oriented fragment of the firefly luciferase gene from plasmid pLuc+ is amplified by PCR from pH108 plasmid DNA using oligonucleotide primers ds\_Luc3 (5' -CGG TCT AGA GGA AGA CGC CAA AAA CAT A-3', SEQ ID NO:3; *Xba*I restriction site underlined) and ds\_Luc2 (5' -CGG AAG CTT AGG CTC GCC TAA TCG CAG TAT CCG GAA TG-3', SEQ ID NO: 2; *Hind*III restriction site underlined). The resulting DNA fragments are purified by electrophoresis through a 1% Tris-acetate gel made from low-melting point agarose (FMC) followed by phenol-chloroform extraction of the excised gel slices containing the PCR products. DNA from the sense product (ds\_Luc1/2) is digested with *BamH*I and *Hind*III and DNA from the antisense product (ds\_Luc3/2) is digested with *Xba*I and *Hind*III according to standard methods (restriction enzymes were obtained from New England Biolabs). The resulting sticky-ended DNA fragments are gel purified as described above. A DNA fragment containing the *mas* 1'promoter (Velten et al. (19984) EMBO J. 3: 2723-2730) is obtained by digesting plasmid CSA104 with *EcoR*I and *Hinc*II and purifying a 564 bp DNA fragment. This fragment is redigested with *BamH*I and the 484 bp *EcoR*I – *BamH*I sub-

fragment containing the *mas* 1' promoter isolated and gel purified. In order to construct plasmid pPH169, DNA from cloning vector pLitmus29 (New England Biolabs) is digested with *EcoRI* and *XbaI*, and the isolated fragment is ligated in a four-way reaction using T4 DNA ligase (New England Biolabs) to the *mas* 1' promoter *EcoRI* – *BamHI* fragment and the sense (*BamHI* – *HindIII*) and antisense (*HindIII* – *XbaI*) ds\_Luc luciferase gene fragments. In order to construct binary vector pPH17Q for Agrobacterium-mediated plant transformation with the ds\_Luc1/2/3 RNA duplex construct, DNA from binary plasmid pSGCHC1 carrying a kanamycin resistance gene for bacterial selection and a hygromycin resistance gene for transgenic plant selection is digested with *EcoRI* and *XbaI*. The resulting 11.6 kb isolated fragment from pSGCHC1 is ligated in a four-way reaction using T4 DNA ligase (New England Biolabs) to the *mas* 1' promoter *EcoRI* – *BamHI* fragment and the sense (*BamHI* – *HindIII*) and antisense (*HindIII* – *XbaI*) ds\_Luc luciferase gene fragments.

#### Transformation of Agrobacterium and Vacuum-infiltration of Arabidopsis plants

Plasmids pPH170 is introduced into *Agrobacterium tumefaciens* GV3101 by electroporation and transformed colonies selected and amplified. Four to five week old plants of *Arabidopsis thaliana* mutant lines expressing luciferase either constitutively (UBQ3 promoter (Norris et al. (1993) PMB 21: 895-906) / UBQ3 + CaMV 35S 5' UTR/luc+; *pPH108*) or inducibly (*Arabidopsis* PR-1 promoter/luc+; *pPH135*, *line 6E*) are vacuum infiltrated with Agrobacterium clones carrying the pPH170 binary T-DNA vector. Transformed plants are co-selected on hygromycin and kanamycin and grown under controlled phytotron conditions for determination of luciferase activity. In addition, luciferase activity in the *pPH135-6E* background is assessed 48 hr after induction with BTH (BTH treatment essentially as described in Lawton et al. Plant J. 10: 71-82). Luciferase activity is quantified using a luminescence-based assay in tissue extracts following the addition of luciferin substrate. Luciferase activity is also monitored *in planta* using a CCD-cooled video imaging system (Hamamatsu).

#### **Example 2: Regulation of the Expression of the *Arabidopsis* GL1 Gene**

The GL1 gene encodes a *myb*-like transcription factor that is required for initiation of normal trichome (leaf hair) formation (Oppenheimer et al. (1991) Cell 67: 483-493). Knock out of GL1 expression early in development results in plants lacking trichomes. The knockout phenotype is easy to identify in young seedlings and is not lethal. Three vectors for constitutive expression and three vectors for Gal4CI-regulated expression are constructed.

The three different vectors to test for each promoter are sense (+) expression, antisense (-) expression, and duplex (+/-) RNA expression of a GL1 gene fragment. The (+) and (-) vectors are controls to compare for their effect on expression of GL1. In each case a 5' fragment from bases #739 to #1781 of the GL1 sequence (GenBank Accession M79448) are used for vector construction.

#### Gal4CI-regulated Expression

The GL1 gene fragments is cloned into the crossing-inducible vector construct pJG304-1 as *NcoI-SacI* fragments. Plasmid pJG304 is derived from pBSSK+. Plasmid pBS SK+

- (Stratagene, LaJolla, CA) is linearized with *SacI*, treated with mung bean nuclease to remove the *SacI* site, and re-ligated with T4 ligase to make pJG201. The 10XGAL4 consensus binding site/CaMV 35S minimal promoter/GUS gene/CaMV terminator cassette is removed from pAT71 with *KpnI* and cloned into the *KpnI* site of pJG201 to make pJG304. Plasmid pJG304 is partially digested with restriction endonuclease *Asp718* to isolate a full-length linear fragment. This fragment is ligated with a molar excess of the 22 base oligonucleotide JG-L (5'-GTA CCT CGA G TC TAG ACT CGA G-3', SEQ ID NO: 4). Restriction analysis is used to identify a clone with this linker inserted 5' to the GAL4 DNA binding site, and this plasmid is designated pJG304DXhol.

The *NcoI* and *SacI* sites are added to the ends of (+) and (-) fragments by synthesizing PCR primers with the appropriate restriction sites to the 5' termini. The (+/-) GL1 fragment is produced by first producing two fragment : a (+) fragment with the *NcoI* site at the 5' terminus and a *HindIII* site at the 3' terminus and a (-) fragment with a *HindIII* site at the 5' terminus and a *SacI* site at the 3' terminus. The duplex unit is produced by ligation of the resulting fragments at the *EcoRI* site. The expression unit contains the Gal4 DNA binding domain, followed by a minimal TATA sequence, and the GL1 gene fragment oriented either (+), (-) or (+/-).

#### Constitutive Expression

The *mas 1'* promoter of mannopine synthase from Agrobacterium(ref), a relatively strong and constitutive in dicot plants is used. As above, the GL (+), (-), and (+/-) fragments are ligated behind the 1' promoter in pBluescript. The three different expression cassettes are ligated into pCIB200 as *EcoRI/Sall* fragments (Uknes et al. (1993) Plant Cell 5: 159-169).

**Example 3: Regulation of the Expression of the Cystathionine Beta Lyase Gene**

The Cystathionine Beta Lyase (CBL) Gene encodes a step in the methionine biosynthesis pathway. The effect of the regulation of its expression in plants is tested using sense and antisense constructs, and double-stranded RNA constructs.

Antisense construct: binary BASTA vector pJG261 is used containing a fragment from the pJG304DXhol vector with an insertion of part of the CBL gene in an antisense orientation (nucleotides #13-1159, Genbank accession #L40511).

Sense construct: same as antisense construct, except the CBL fragment is in the opposite orientation. This construct contains the ATG start codon and most of the CBL ORF and serves as a control for regulation of the expression of the CBL gene.

Double-stranded RNA construct: A CBL gene fragment (#13-1159) in the sense orientation is inserted into the *Sall* site of vector pJG304-1 downstream of the antisense orientation version of the CBL gene. A linker of about 10 bp is present between the two copies of CBL.

**Example 4: Requirements for Construction of Plant Expression Cassettes**

Gene sequences intended for expression in transgenic plants are firstly assembled in expression cassettes behind a suitable promoter and upstream of a suitable transcription terminator. All requirement for constructions of plant expression cassettes apply to the DNA molecules of the present invention and are carried out using techniques well-known in the art.

**Promoter Selection**

The selection of promoter used in expression cassettes determines the spatial and temporal expression pattern of the DNA molecule in the transgenic plant. Selected promoters express DNA molecule in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and this selection reflects the desired location of biosynthesis of a RNA fragment encoded by the DNA molecule. Alternatively, the selected promoter may drive expression of the DNA molecule under a light-induced or other temporally regulated promoter. A further alternative is that the selected promoter be chemically regulated. This provides the possibility of

inducing the expression of the DNA molecule only when desired and caused by treatment with a chemical inducer.

#### Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription and, preferably, correct polyadenylation. Appropriate transcriptional terminators and those which are known to function in plants and include the CaMV 35S terminator, the *tm1* terminator, the nopaline synthase terminator, the pea *rbcS E9* terminator. These can be used in both monocotyledons and dicotyledons.

#### Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the DNA molecule of this invention to increase its expression in transgenic plants.

Various intron sequences have been shown to enhance expression, particularly in monocotyledonous cells. For example, the introns of the maize *Adh1* gene have been found to significantly enhance the expression of the wild-type gene under its cognate promoter when introduced into maize cells. Intron 1 is found to be particularly effective and enhanced expression in fusion constructs with the chloramphenicol acetyltransferase gene (Callis *et al.*, *Genes Develop.* 1: 1183-1200 (1987)). In the same experimental system, the intron from the maize *bronze1* gene had a similar effect in enhancing expression (Callis *et al.*, *supra*). Intron sequences have been routinely incorporated into plant transformation vectors, typically within the non-translated leader.

A number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells.

Specifically, leader sequences from Tobacco Mosaic Virus (TMV, the "Ω-sequence"), Maize Chlorotic Mottle Virus (MCMV), and Alfalfa Mosaic Virus (AMV) have been shown to be effective in enhancing expression (*e.g.* Gallie *et al.* *Nucl. Acids Res.* 15: 8693-8711 (1987); Skuzeski *et al.* *Plant Molec. Biol.* 15: 65-79 (1990)).

#### **Example 5: Examples of Expression Cassette Construction**

The present invention encompasses the expression of a DNA molecule of the present invention under the regulation of any promoter which is expressible in plants, regardless of the origin of the promoter. Therefore the DNA molecule is inserted into any of the

expression cassette using techniques well-known in the art. These expression cassettes can then be easily transferred to the plant transformation vectors described below. Furthermore, the invention also encompasses the use of any plant-expressible promoter in conjunction with any further sequences required or selected for the expression of the DNA molecule. Such sequences include, but are not restricted to, transcriptional terminators, extraneous sequences to enhance expression (such as introns [e.g. *Adh* intron 1], viral sequences [e. g. TMV- $\Omega$ ]).

#### Constitutive Expression: the CaMV 35S Promoter

Construction of the plasmid pCGN1761 is described in the published patent application EP 0 392 225. pCGN1761 contains the "double" 35S promoter and the *tm*/transcriptional terminator with a unique *EcoRI* site between the promoter and the terminator and has a pUC-type backbone. A derivative of pCGN1761 is constructed which has a modified polylinker which includes *NotI* and *XhoI* sites in addition to the existing *EcoRI* site. This derivative is designated pCGN1761ENX. pCGN1761ENX is useful for the cloning of cDNA sequences or gene sequences (including microbial ORF sequences) within its polylinker for the purposes of their expression under the control of the 35S promoter in transgenic plants. The entire 35S promoter-gene sequence-*tm*/terminator cassette of such a construction can be excised by *HindIII*, *SphI*, *Sall*, and *XbaI* sites 5' to the promoter and *XbaI*, *BamHI* and *BglII* sites 3' to the terminator for transfer to transformation vectors. Furthermore, the double 35S promoter fragment can be removed by 5' excision with *HindIII*, *SphI*, *Sall*, *XbaI*, or *PstI*, and 3' excision with any of the polylinker restriction sites (*EcoRI*, *NotI* or *XhoI*) for replacement with another promoter.

Accordingly, a DNA molecule of the present invention is inserted into pCGN1761ENX for constitutive expression under the control of the CaMV 35S promoter.

#### Expression under a Chemically Regulatable Promoter

This section describes the replacement of the double 35S promoter in pCGN1761ENX with any promoter of choice; by way of example the chemically regulated PR-1a promoter is described. The promoter of choice is preferably excised from its source by restriction enzymes, but can alternatively be PCR-amplified using primers which carry appropriate terminal restriction sites. Should PCR-amplification be undertaken, then the promoter should be resequenced to check for amplification errors after the cloning of the amplified promoter in the target vector. The chemically regulatable tobacco PR-1a promoter is

cleaved from plasmid pCIB1004 (see EP 0 332 104) and transferred to plasmid pCGN1761ENX. pCIB1004 is cleaved with *NcoI* and the resultant 3' overhang of the linearized fragment is rendered blunt by treatment with T4 DNA polymerase. The fragment is then cleaved with *HindIII* and the resultant PR-1a promoter containing fragment is gel purified and cloned into pCGN1761ENX from which the double 35S promoter has been removed. This is done by cleavage with *XbaI* and blunting with T4 polymerase, followed by cleavage with *HindIII* and isolation of the larger vector-terminator containing fragment into which the pCIB1004 promoter fragment is cloned. This generates a pCGN1761ENX derivative with the PR-1a promoter and the *tm*/terminator and an intervening polylinker with unique *EcoRI* and *NotI* sites.

A DNA molecule of the present invention is inserted into this vector, and the fusion product (*i.e.* promoter-gene-terminator) is subsequently transferred to any selected transformation vector, including those described in this application, thus providing for chemically inducible expression of the DNA molecule.

#### Constitutive Expression: the Actin Promoter

Several isoforms of actin are known to be expressed in most cell types and consequently the actin promoter is a good choice for a constitutive promoter. In particular, the promoter from the rice *Act1* gene has been cloned and characterized (McElroy *et al.* Plant Cell 2: 163-171 (1990)). A 1.3 kb fragment of the promoter is found to contain all the regulatory elements required for expression in rice protoplasts. Furthermore, numerous expression vectors based on the *Act1* promoter have been constructed specifically for use in monocotyledons (McElroy *et al.* Mol. Gen. Genet. 231: 150-160 (1991)). These incorporate the *Act1*-intron 1, *Adh1* 5' flanking sequence and *Adh1*-intron 1 (from the maize alcohol dehydrogenase gene) and sequence from the CaMV 35S promoter. Vectors showing highest expression are fusions of 35S and the *Act1* intron or the *Act1* 5' flanking sequence and the *Act1* intron. The promoter expression cassettes described by McElroy *et al.* (Mol. Gen. Genet. 231: 150-160 (1991)) is easily modified for the expression of a DNA molecule of the present invention and are particularly suitable for use in monocotyledonous hosts. For example, promoter containing fragments are removed from the McElroy constructions and used to replace the double 35S promoter in pCGN1761ENX, which is then available for the insertion of specific gene sequences. The fusion genes thus constructed are transferred to appropriate transformation vectors. In a separate report the rice *Act1*

promoter with its first intron has also been found to direct high expression in cultured barley cells (Chibbar *et al.* Plant Cell Rep. 12: 506-509 (1993)).

A DNA molecule of the present invention is inserted downstream of such promoter, and the fusion products (*i.e.* promoter-gene-terminator) are subsequently transferred to any selected transformation vector, including those described in this application.

#### Constitutive Expression: the Ubiquitin Promoter

Ubiquitin is another gene product known to accumulate in many cell types and its promoter has been cloned from several species for use in transgenic plants (*e.g.* sunflower - Binet *et al.* Plant Science 79: 87-94 (1991), maize - Christensen *et al.* Plant Molec. Biol. 12: 619-632 (1989)). The maize ubiquitin promoter has been developed in transgenic monocot systems and its sequence and vectors constructed for monocot transformation are disclosed in the patent publication EP 0 342 926. Further, Taylor *et al.* (Plant Cell Rep. 12: 491-495 (1993)) describe a vector (pAHC25) which comprises the maize ubiquitin promoter and first intron and its high activity in cell suspensions of numerous monocotyledons when introduced via microprojectile bombardment. The ubiquitin promoter is clearly suitable for the expression of a DNA molecule of the present invention in transgenic plants, especially monocotyledons. Suitable vectors are derivatives of pAHC25 or any of the transformation vectors described in this application, modified by the introduction of the appropriate ubiquitin promoter and/or intron sequences.

A DNA molecule of the present invention is therefore inserted into any of these vector, and the fusion products (*i.e.* promoter-gene-terminator) are used for transformation of plants, resulting in constitutive expression of the DNA molecule.

#### Root Specific Expression

A preferred pattern of expression for a DNA molecule of the instant invention is root expression. Expression of the nucleotide sequence only in root tissue has the advantage of altering the expression of a target gene only in roots, without a concomitant alteration of its expression in leaf and flower tissue and seeds. A suitable root promoter is that described by de Framond (FEBS 290: 103-106 (1991)) and also in the published patent application EP 0 452 269. This promoter is transferred to a suitable vector such as pCGN1761ENX and the DNA molecule is inserted into such vector. The entire promoter-gene-terminator cassette is subsequently transferred to a transformation vector of interest.

Wound Inducible Promoters

Numerous such promoters have been described (e.g. Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek *et al.* Plant Molec. Biol. 22: 129-142 (1993), Warner *et al.* Plant J. 3: 191-201 (1993)) and all are suitable for use with the instant invention.

Logemann *et al.* (*supra*) describe the 5' upstream sequences of the dicotyledonous potato *wun1* gene. Xu *et al.* (*supra*) show that a wound inducible promoter from the dicotyledon potato (*pin2*) is active in the monocotyledon rice. Further, Rohrmeier & Lehle (*supra*) describe the cloning of the maize *Wip1* cDNA which is wound induced and which can be

- used to isolated the cognate promoter using standard techniques. Similarly, Firek *et al.* (*supra*) and Warner *et al.* (*supra*) have described a wound induced gene from the monocotyledon *Asparagus officinalis* which is expressed at local wound and pathogen invasion sites. Using cloning techniques well known in the art, these promoters can be transferred to suitable vectors, fused to a DNA molecule of this invention, and used to express these genes at the sites of insect pest infection.

Pith Preferred Expression

Patent application WO 93/07278 describes the isolation of the maize *trpA* gene which is preferentially expressed in pith cells. Using standard molecular biological techniques, this promoter or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a DNA molecule of the present invention in a pith-preferred manner. In fact, fragments containing the pith-preferred promoter or parts thereof are transferred to any vector and modified for utility in transgenic plants. Pith preferred expression of the DNA molecule is achieved by inserting the DNA molecule in such vector.

Pollen-Specific Expression

Patent Application WO 93/07278 further describes the isolation of the maize calcium-dependent protein kinase (CDPK) gene which is expressed in pollen cells. The gene sequence and promoter extend up to 1400 bp from the start of transcription. Using standard molecular biological techniques, this promoter or parts thereof, is transferred to a vector such as pCGN1761 where it replaces the 35S promoter and is used to drive the expression of a DNA molecule of the present invention in a pollen-specific manner. In fact

fragments containing the pollen-specific promoter or parts thereof can be transferred to any vector and modified for utility in transgenic plants.

#### Leaf-Specific Expression

A maize gene encoding phosphoenol carboxyliase (PEPC) has been described by Hudspeth & Grula (Plant Molec Biol 12: 579-589 (1989)). Using standard molecular biological techniques the promoter for this gene is used to drive the expression of a DNA molecule of the present invention in a leaf-specific manner in transgenic plants.

#### **Example 6: Construction of Plant Transformation Vectors**

Numerous transformation vectors are available for plant transformation, and a DNA molecule of this invention is inserted into any of the expression cassettes described above, such that they are capable of expressing the DNA molecule in desirable cells, under appropriate conditions. A nucleotide sequence-containing expression cassette is then incorporated into any appropriate transformation vector described below.

The selection of vector for use will depend upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers may be preferred. Selection markers used routinely in transformation include the *nptII* gene which confers resistance to kanamycin and related antibiotics (Messing & Vierra, Gene 19: 259-268 (1982); Bevan *et al.*, Nature 304:184-187 (1983)), the *bar* gene which confers resistance to the herbicide phosphinothricin (White *et al.*, Nucl Acids Res 18: 1062 (1990), Spencer *et al.* Theor Appl Genet 79: 625-631(1990)), the *hph* gene which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol Cell Biol 4: 2929-2931), and the *dhfr* gene, which confers resistance to methotrexate (Bourouis *et al.*, EMBO J. 2(7): 1099-1104 (1983)).

#### **Vectors Suitable for *Agrobacterium* Transformation**

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, Nucl. Acids Res. (1984)) and pVictor HINK (SEQ ID NO: 5). Below the construction of two typical vectors is described.

Construction of pCIB200 and pCIB2001

The binary vectors pCIB200 and pCIB2001 are used for the construction of recombinant vectors for use with *Agrobacterium* and is constructed in the following manner. pTJS75kan is created by *NarI* digestion of pTJS75 (Schmidhauser & Helinski, J Bacteriol. 164: 446-455 (1985)) allowing excision of the tetracycline-resistance gene, followed by insertion of an *AccI* fragment from pUC4K carrying an NPTII (Messing & Vierra, Gene 19: 259-268 (1982); Bevan *et al.*, Nature 304: 184-187 (1983); McBride *et al.*, Plant Molecular Biology 14: 266-276 (1990)). *XhoI* linkers are ligated to the *EcoRV* fragment of pCIB7 which contains the left and right T-DNA borders, a plant selectable *nos/nptII* chimeric gene and the pUC polylinker (Rothstein *et al.*, Gene 53: 153-161 (1987)), and the *XhoI*-digested fragment is cloned into *Sall*-digested pTJS75kan to create pCIB200 (see also EP 0 332 104). pCIB200 contains the following unique polylinker restriction sites: *EcoRI*, *SstI*, *KpnI*, *BglIII*, *XbaI*, and *Sall*. pCIB2001 is a derivative of pCIB200 which created by the insertion into the polylinker of additional restriction sites. Unique restriction sites in the polylinker of pCIB2001 are *EcoRI*, *SstI*, *KpnI*, *BglIII*, *XbaI*, *Sall*, *MluI*, *BclI*, *AvrII*, *Apal*, *HpaI*, and *StuI*. pCIB2001, in addition to containing these unique restriction sites also has plant and bacterial kanamycin selection, left and right T-DNA borders for *Agrobacterium*-mediated transformation, the RK2-derived *trfA* function for mobilization between *E. coli* and other hosts, and the *OriT* and *OriV* functions also from RK2. The pCIB2001 polylinker is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

Any one of the plant expression cassettes described above and comprising a DNA molecule of the present invention are inserted into pCIB2001, preferably using the polylinker.

Construction of pCIB10 and Hygromycin Selection Derivatives thereof

The binary vector pCIB10 contains a gene encoding kanamycin resistance for selection in plants, T-DNA right and left border sequences and incorporates sequences from the wide host-range plasmid pRK252 allowing it to replicate in both *E. coli* and *Agrobacterium*. Its construction is described by Rothstein *et al.* (Gene 53: 153-161 (1987)). Various derivatives of pCIB10 have been constructed which incorporate the gene for hygromycin B phosphotransferase described by Gritz *et al.* (Gene 25: 179-188 (1983)). These derivatives enable selection of transgenic plant cells on hygromycin only (pCIB743), or hygromycin and kanamycin (pCIB715, pCIB717). This vectors is used transform an expression cassette comprising a DNA molecule of the present invention.

### Vectors Suitable for non-*Agrobacterium* Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences can be utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques which do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (e.g. PEG and electroporation), microinjection or pollen transformation (US Patent 5,629,183). The choice of vector depends largely on the preferred selection for the species being transformed. Below, the construction of some typical vectors is described.

#### Construction of pCIB3064

pCIB3064 is a pUC-derived vector suitable for direct gene transfer techniques in combination with selection by the herbicide basta (or phosphinothricin). The plasmid pCIB246 comprises the CaMV 35S promoter in operational fusion to the *E. coli* GUS gene and the CaMV 35S transcriptional terminator and is described in the PCT published application WO 93/07278. The 35S promoter of this vector contains two ATG sequences 5' of the start site. These sites are mutated using standard PCR techniques in such a way as to remove the ATGs and generate the restriction sites *SspI* and *PvuII*. The new restriction sites are 96 and 37 bp away from the unique *Sall* site and 101 and 42 bp away from the actual start site. The resultant derivative of pCIB246 is designated pCIB3025. The GUS gene is then excised from pCIB3025 by digestion with *Sall* and *SacI*, the termini rendered blunt and religated to generate plasmid pCIB3060. The plasmid pJIT82 is obtained from the John Innes Centre, Norwich and the a 400 bp *SmaI* fragment containing the *bar* gene from *Streptomyces viridochromogenes* is excised and inserted into the *HpaI* site of pCIB3060 (Thompson *et al.* EMBO J 6: 2519-2523 (1987)). This generated pCIB3064 which comprises the *bar* gene under the control of the CaMV 35S promoter and terminator for herbicide selection, a gene fro ampicillin resistance (for selection in *E. coli*) and a polylinker with the unique sites *SphI*, *PstI*, *HindIII*, and *BamHI*. This vector is suitable for the cloning of plant expression cassettes containing their own regulatory signals to direct expression of a DNA molecule of the present invention.

Construction of pSOG19 and pSOG35

pSOG35 is a transformation vector which utilizes the *E. coli* gene dihydrofolate reductase (DHFR) as a selectable marker conferring resistance to methotrexate. PCR is used to amplify the 35S promoter (~800 bp), intron 6 from the maize Adh1 gene (~550 bp) and 18 bp of the GUS untranslated leader sequence from pSOG10. A 250 bp fragment encoding the *E. coli* dihydrofolate reductase type II gene is also amplified by PCR and these two PCR fragments are assembled with a *SacI-PstI* fragment from pBI221 (Clontech) which comprised the pUC19 vector backbone and the nopaline synthase terminator. Assembly of these fragments generated pSOG19 which contains the 35S promoter in fusion with the intron 6 sequence, the GUS leader, the DHFR gene and the nopaline synthase terminator. Replacement of the GUS leader in pSOG19 with the leader sequence from Maize Chlorotic Mottle Virus (MCMV) generated the vector pSOG35. pSOG19 and pSOG35 carry the pUC gene for ampicillin resistance and have *HindIII*, *SphI*, *PstI* and *EcoRI* sites available for the cloning of foreign sequences, in particular a DNA molecule of the present invention.

**Example 7: Chloroplast Transformation**Transformation vectors

For expression of a DNA molecule of the present invention in plant plastids, plastid transformation vector pPH143 (WO 97/32011, example 36) is used. The DNA molecule is inserted into pPH143 thereby replacing the PROTOX coding sequence. This vector is then used for plastid transformation and selection of transformants for spectinomycin resistance. Alternatively, the DNA molecule is inserted in pPH143 so that it replaces the aadH gene. In this case, transformants are selected for resistance to PROTOX inhibitors.

Chloroplast Transformation

Seeds of *Nicotiana tabacum* c.v. 'Xanthi nc' were germinated seven per plate in a 1" circular array on T agar medium and bombarded 12-14 days after sowing with 1 µm tungsten particles (M10, Biorad, Hercules, CA) coated with DNA from plasmids pPH143 and pPH145 essentially as described (Svab, Z. and Maliga, P. (1993) *PNAS* 90, 913-917). Bombarded seedlings were incubated on T medium for two days after which leaves were excised and placed abaxial side up in bright light (350-500 µmol photons/m<sup>2</sup>/s) on plates of RMOP medium (Svab, Z., Hajdukiewicz, P. and Maliga, P. (1990) *PNAS* 87, 8526-8530) containing 500 µg/ml spectinomycin dihydrochloride (Sigma, St. Louis, MO). Resistant shoots

appearing underneath the bleached leaves three to eight weeks after bombardment were subcloned onto the same selective medium, allowed to form callus, and secondary shoots isolated and subcloned. Complete segregation of transformed plastid genome copies (homoplasmicity) in independent subclones was assessed by standard techniques of Southern blotting (Sambrook et al., (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor). BamHI/EcoRI-digested total cellular DNA (Mettler, I. J. (1987) *Plant Mol Biol Reporter* 5, 346-349) was separated on 1% Tris-borate (TBE) agarose gels, transferred to nylon membranes (Amersham) and probed with <sup>32</sup>P-labeled random primed DNA sequences corresponding to a 0.7 kb BamHI/HindIII DNA fragment from pC8 containing a portion of the *rps7/12* plastid targeting sequence. Homoplasmic shoots are rooted aseptically on spectinomycin-containing MS/IBA medium (McBride, K. E. et al. (1994) *PNAS* 91, 7301-7305) and transferred to the greenhouse.

**Example 8: Construction of a chimeric gene cassette encoding a sense and antisense (duplex) RNA fragment for the coat protein gene from BWYV, driven by the *RoIC* promoter**

An 0.6 Kb 'sense' oriented fragment of the beet western yellows virus (BWYV), a so-called virus yellow, coat protein (CP) gene is amplified from plasmid pZU046 using primers HiNK025bis (5' -CAA TTA CCA TGG ACA CGG TCG TGG-3', SEQ ID NO: 6; *NcoI* restriction site underlined), and HiNK226 (5' -GCC AAA TGT TTG AAC GCT GCA GCC TAT TTG-3', SEQ ID NO: 7; *PstI* restriction site underlined). Alternatively the fragment is amplified from plasmid pBW17 (Veidt et al, Nucleic Acids Research 16: 9917-9932, 1988; accession number X13063) using primers HiNK025bis2 (5' -AAT CGT CCA TGG ATA CGG TCG TGG-3', SEQ ID NO: 8; nucleotides 3475 to 3498, *NcoI* restriction site underlined), and HiNK226bis (5' -CTA GGG CCG GGT TCC TCT GCA GCC TAT TTG-3', SEQ ID NO: 9; nucleotides 4114 to 4085, *PstI* restriction site underlined). Taq DNA Polymerase (Life Technologies) is used in 25μl reactions according to the manufacturer's prescription applying 30 cycles of 94°C/30 sec, 55°C /30 sec, 72°C/90 sec (+2 sec/cycle). The resulting PCR fragment is purified by electrophoresis through a 1% Tris-acetate gel made from Seakem GTG agarose (FMC), followed by an extraction of the gel slices containing the PCR product with QIAquick Gel Extraction Kit (QIAGEN). The PCR product is subsequently digested with *NcoI* and *PstI* (all restriction enzymes were supplied by Life Technologies) according to standard methods and again gel purified. The purified fragment

is ligated between the *Ro/C* promoter and the *Nos* terminator using T4 DNA ligase (Life Technologies). The resulting clone is named pHiNK138.

In a similar manner as described above a 1.4 Kb 'antisense' oriented BWYV CP fragment is amplified from plasmid pZU174A using primers HiNK251 (5'-CTC CCA GGT TGA GAC TGC CCT GCA GTG CCC A-3', SEQ ID NO: 10; *PstI* restriction site underlined) and HiNK228 (5'-TTA CCA TGC ATA CGG TCG TGG GTA GG-3', SEQ ID NO: 11; *NsiI* restriction site underlined) or from plasmid pBW17 using primers HiNK251 (nucleotides 4844 to 4814) and HiNK228bis (5'-CGT TAA TGC ATA CGG TCG TGG GTA GG-3', SEQ ID NO: 12; nucleotides 3478 to 3503, *NsiI* restriction site underlined). Upon gel purification the PCR product is digested with *NsiI* and *PstI*. The 4.9 Kb plasmid pHiNK138 is linearised with *PstI* and dephosphorylated using the Thermosensitive Alkaline Phosphatase (Life Technologies). Both the vector and the PCR fragment are gel purified, followed by the bidirectional ligation of the PCR fragment into pHiNK138. The orientation generating the duplex RNA for the CP gene (SEQ ID NO: 13) is identified by restriction site analysis, yielding plasmid pHiNK152 in which the inverted repeat consists of the 0.6 Kb CP gene separated by the 0.7 Kb spacer sequence derived from the BWYV genome downstream of the CP gene, referred to as ORF6. The spacer sequence is in the antisense orientation. Finally, the said gene cassette is transferred to the proprietary binary vector pVictorHiNK carrying phosphomannose isomerase as selectable marker gene (WO 94/20627), yielding pHiNK179.

**Example 9.1: Construction of a chimeric gene cassette encoding a sense and antisense (duplex) RNA fragment for the replicase gene from BNYVV, driven by the *Arabidopsis Ubi3int* promoter**

Total RNA is extracted from sugar beet root infected by the beet necrotic yellow vein virus (BNYVV), a furovirus, using the RNAeasy Plant mini kit from QIAGEN. In order to amplify the 3' end of the BNYVV replicase gene (RNA1) the RNA is reverse transcribed to produce a cDNA using the Superscript<sup>TM</sup>II RNase H-Reverse Transcriptase (RT) (Life Technologies) and the reverse primer HiNK285 (5'-TCG TAG AAG AG A ATT CAC CCA AAC TAT CC-3', SEQ ID NO: 14). Primer HiNK285 is located between nucleotides 6378 and 6405 of the BNYVV RNA1 sequence (accession number D00115) and designed to introduce an *EcoRI* site. The RT reaction is subsequently used as template for two PCR reactions :

- Reaction A using primer HiNK283 (5' -AAG AAT TGC AGG ATC CAC AGG CTC GGT AC-3', SEQ ID NO: 15) located between nucleotides 5168 bp and 5178 bp of BNYVV RNA1 designed to introduce a *BamHI* site, and primer HiNK284 (5' -TTC CAA CGA ATT CGG TCT CAG AC A-3', SEQ ID NO: 16) located between nucleotides 5597 and 5620 of BNYVV RNA1 designed to introduce an *EcoRI* site.
- Reaction B using primer HiNK283 in combination with primer HiNK285, both described above.

The thus obtained RT-PCR products share the BNYVV RNA1 sequence between nucleotides 5168-5620 that constitutes the future RNA duplex. The future spacer sequence

- corresponds to nucleotides 5621-6405 bp of BNYVV RNA1 present at the RT-PCR product obtained with primers HiNK283 and HiNK285.

*Taq* DNA Polymerase (Life Technologies) is used in 25 $\mu$ l reactions according to the suppliers's prescription applying 30 cycles of 94°C/30 sec, 55°C/30 sec, 72°C/90 sec(+2 sec/cycle). The resulting RT-PCR products are purified by electrophoresis through a 1% Tris-acetate gel made from Seakem GTG agarose (FMC), followed by an extraction of the gel slices containing the amplification products with the QIAquick Gel Extraction Kit (QIAGEN). After gel purification, the RT-PCR products are digested with restriction enzymes *BamHI* and *EcoRI* (Life Technologies) according to standard methods and purified as described above.

Finally the RT-PCR products are cloned between the *Arabidopsis* Ubiquitin3 (*Ubi3int*) promoter and the *Nos* terminator by means of a three-way ligation reaction using T4 DNA ligase (Life Technologies). The two resulting clones are named pHINK181 (spacer in antisense orientation, see SEQ ID NO: 17) and pHINK184 (spacer in sense orientation, see SEQ ID NO: 18).

In order to construct the binary vectors for the *Agrobacterium*-mediated transformation of sugar beet, DNA from binary vector pVictorHiNK carrying the phophomannose isomerase gene as selectable marker (WO 94/20627), as well as plasmids pHINK181 and pHINK184, are digested with *AscI* and *PacI* (New England Biolabs) and the vector and insert fragments purified by electrophoresis as described above. The resulting 7.7 kb pVictorHiNK vector fragment is ligated using T4 DNA ligase (Life Technologies) to the gene cassettes encoding the duplex RNA for the BNYVV replicase gene yielding pHINK187 (antisense spacer) and pHINK188 (sense spacer) respectively.

**Example 9.2: *Agrobacterium*-mediated transformation of sugar beet**

Methods for the *Agrobacterium*-mediated transformation of plants species are well established and known to a person skilled in the art, and may vary for the explant type, the *Agrobacterium* strain, or the selectable marker and regeneration system used. The protocol here below describes the *Agrobacterium*-mediated transformation of sugar beet using cotyledons as source for explants and mannose-6-phosphate isomerase as selectable marker gene (Joersbo et al, Molecular Breeding 4: 111-117, 1998). Upon surface sterilization sugar beet seeds are germinated on water agar and under dim light at a temperature of approximately 12°C. Fully developed cotyledons are removed from the seedling by a transversal cut just below the nodal region and both cotyledons torn apart by gentle pulling and cutting. Cotyledon explants are inoculated by dipping them into a suspension of *Agrobacterium* strain EHA101 carrying the appropriate transformation vector diluted in MS medium pH 5.2, supplemented with 20 g/l sucrose, 0.25 mg/l BA, 0.05 mg/l NAA, 500 µM acetosyringone diluted to an optical density (OD600) from 0.1 to 0.3. After five minutes of incubation explants are removed from the *Agrobacterium* suspension, dipped on sterile filter paper to remove access of the inoculation suspension, and transferred to co-cultivation plates. The co-cultivation plates consist of petri dishes containing 1/10 MS medium pH 5.7, 30 g/l sucrose, 200 µM acetosyringone, solidified with 4.7 g/l agarose and covered with a filter paper moistened with 1.5 ml TXD medium (MS salts supplemented with PGO vitamins, 0.005 mg/l kinetin, 4 mg/l CPA (*p*-chlorophenoxy acetic acid), 30 g/l sucrose, pH 5.7) on the top of the solidified medium. Explants are co-cultivated during 4 days at 21°C and under dim light, and subsequently transferred to selective regeneration medium consisting of MS medium pH 5.9 supplemented with 20 g/l sucrose, 1.25 g/l mannose, 0.25 mg/l BA, 0.05 mg/l NAA, 500 mg/l carbenicillin, and solidified with 9 g/l agar. Every third week the explants are subcultured to fresh media containing gradually increasing concentrations of mannose to a maximum of 15 g/l. After 12 weeks of selection and regeneration at a temperature of 21°C, regenerated shoots are harvested, rooted and analyzed for PMI activity essentially according to the coupled enzyme assay described by Feramisco and co-workers (Feramisco et al, Biochem. Biophys. Res. Comm. 55: 636-641, 1973). Positive plants are potted in soil and finally transferred to the greenhouse.

### Example 9.3: Screening for resistance to rhizomania

Upon sowing or potting to soil, seedlings or T0 transformants are first allowed to establish a sufficiently developed root system for a period of approximately four weeks, prior to their transfer to soil infested with *Polomyxa betae* carrying BNYVV. Infested soils are collected from rhizomania infected fields in Germany. During the resistance assay plants are grown in 12 cm pots at a temperature of approximately 21°C and light period of 16 hours. Four weeks after transplantation into the infested soil, plants are pulled from the soil and the bottom half of the root system cleaned from any adhering dirt by rinsing with water. Sap from a random sample of 0.5 g of root tissue is collected by means of a Pollähne press and added to 10 ml of extraction buffer consisting of phosphate buffered saline pH 7.2, supplemented with 2% PVP and 0.2% ovalbumin. The amount of virus present in the samples (clones are obtained by *in vitro* propagation) is determined by means of the triple antibody sandwich (TAS) ELISA for BNYVV commercialized by Adgen Ltd, Scotland, UK, essentially following the supplier's instruction. A standard curve is included on each plate to calculate the virus content of the root samples from the measured absorbance values. Non-transformed susceptible sugar beet plants serve as negative controls, plants carrying the C28 gene for natural rhizomania resistance as positive controls. Table 1 summarizes the results of transformation events obtained with plasmid pHINK188.

Table 1:

| Event          | Clone number | ELISA value | Virus content ng/ml |
|----------------|--------------|-------------|---------------------|
| Event 279-15-A | 1            | 3.265       | >900                |
|                | 2            | 3.420       | >900                |
|                | 3            | 2.987       | >900                |
| Event 284-22-A | 1            | 0.119       | 4                   |
| Event 284-22-G | 1            | 0.022       | 0                   |
|                | 2            | 0.006       | 0                   |
| Event 284-22-I | 1            | 0.010       | 0                   |
| Event 284-22-M | 1            | 1.400       | 216                 |
|                | 2            | 1.127       | 138                 |
| Event 284-22-Q | 1            | 0.447       | 29                  |
|                | 2            | 0.049       | 1                   |
| Event 284-22-U | 1            | 3.420       | >900                |
|                | 2            | 3.582       | >900                |

| Event                | Clone number | ELISA value | Virus content ng/ml |
|----------------------|--------------|-------------|---------------------|
| Event 284-22-1F      | 1            | 3.945       | >900                |
|                      | 2            | 0.131       | 4                   |
| C28 positive control | 1            | 0.677       | 56                  |
|                      | 2            | 0.679       | 56                  |
| C28 positive control | 3            | 0.377       | 22                  |
|                      | 4            | 0.756       | 67                  |
| C28 positive control | 5            | 1.122       | 137                 |
|                      | 6            | 0.640       | 51                  |
| Negative control A   | 1            | 3.186       | >900                |
|                      | 2            | 3.362       | >900                |
| Negative control A   | 3            | 3.487       | >900                |
|                      | 4            | 3.311       | >900                |
| Negative control A   | 5            | 3.478       | >900                |
|                      | 1            | 3.678       | >900                |
| Negative control B   | 2            | 3.582       | >900                |
|                      | 3            | 3.326       | >900                |
| Negative control B   | 4            | 3.502       | >900                |
|                      | 5            | 3.330       | >900                |
| Negative control B   | 6            | 3.439       | >900                |
|                      | 7            | 3.439       | >900                |
| Negative control B   | 8            | 3.682       | >900                |

**Example 10: Construction of a plant transformation vector for Zucchini yellow mosaic potyvirus (ZYMV) and Papaya ringspot potyvirus (PRSV) resistance in Melon:**

The NOS terminator (Bevan, M., et al, 1983 *Nucleic Acids Res.* 11 (2), 369-385) is cloned as 260 bp HindIII/PstI fragment into the plasmid pZO1560 digested with HindIII/PstI.

PZO1560 is a pUC derived plasmid in which the multiple cloning site has been replaced by a more versatile one. The new construct obtained after insertion of the NOS terminator is named pZU533.

The 1728 bp Ubi3 promoter/intron fragment (Callis, J., et al, (1995 *Genetics* 139 (2), 921-939) is isolated by digestion with BamHI followed by a T4 DNA polymerase treatment and KpnI digestion. This fragment is cloned into pZU533 digested with SmaI. The new construct is named pZU615.

Additional DNA fragments to be inserted into pZU615 are firstly amplified by PCR using Pfx DNA polymerase and the PCR fragments obtained are cloned into pBluescript SK+.

To amplify a 513 bp Actin2 IntronL (leader intron) fragment two primers are designed based on the sequence from An et al, *The Plant Journal*: 10: 107-121, 1996. The 5' primer (ZUP1563: 5' -GGCCGGATCCGCTAGCCCCGGCCGCTCTTCTTTCCAAGG-3', SEQ ID NO: 19) anneals directly upstream of the 5' splice site and adds a BamHI, a NheI and a SacII restriction site to the 5'-end of the Actin2 IntronL fragment to be amplified. The 3' primer (ZUP1564: 5' -CCCGCCATGGGTGACGCCATTATGAGCTGC-3', SEQ ID NO: 20) anneals directly downstream of the 3' splice site and adds a Sall and a NcoI restriction site to the 3'-end of the Actin2 IntronL fragment to be amplified. The PCR fragment amplified with ZUP1563 and 1564 is cloned in the EcoRV site of pBluescript. The new plasmid is named pZU611. To provide plasmid pZU615 with the Act2 IntronL a 499 bp BamH/NcoI Act2 IntronL fragment is isolated from pZU611 and cloned in pZU615 digested with BamHI and NcoI downstream of the Ubi3 promoter/intron and upstream of the NOS terminator. The new construct is designated pZU616. The insertion of this fragment simultaneously provides the cassette with five additional restriction sites for the next three cloning steps.

To amplify a non-translated (nt) 739 bp PRSV CP fragment (Shyi-Dong, Y., et al, (1992).

*Journal of General Virology* 73, 2531-2541) two primers are designed based on the sequence of a French field isolate from Shyi-Dong Yeh. The 5' primer (ZUP1565: 5' - CCCGCCATGGATCCGATGATTCTACCGAGAATTAAGGG -3', SEQ ID NO: 21) anneals 285 bp downstream of the start codon of PRSV CP and adds a NcoI and a BamHI restriction site to the 5'-end of the non-translated PRSV CP fragment. The 3' primer (ZUP1566: 5' - GGGCGCTAGCCTAATGCTTATATAGTACC-3', SEQ ID NO: 22) anneals 55 bp downstream of the PRSV CP stop codon and adds a NheI restriction site to the 3'-end of the non-translated PRSV CP fragment. The amplified PCR fragment is cloned in the EcoRV site of pBluescript and the new plasmid is designated pZU612.

To amplify a 735 bp non-translated ZYMV CP fragment (Gal-On, A., et al, (1990). *Gene* 87, 273-277) two primers are designed based on the sequence of a French field isolate from Gal-On, A.. The 5' primer (ZUP1567: 5' - GGGCGCTAGCCTTGCTGGAGTATAAGCCGG -3', SEQ ID NO: 23) anneals 253 bp downstream of the start codon of ZYMV CP and includes a NheI restriction site at the 5'-end of the ZYMV CP non-translated fragment. The 3' primer (ZUP1568: 5' - GGGCGTCGACCGCGGGCTTAAAGGTGGGAGGCC -3', SEQ ID NO: 24) anneals 89 bp downstream of the ZYMV CP stop codon and includes SacII and a Sall

restriction sites at the 3' end of the non-translated ZYMV CP fragment. The amplified PCR fragment is cloned in the EcoRV site of pBluescript. The new plasmid is named pZU613. A ZYMV CP non-translated fragment is subsequently cloned into pZU616 downstream of the Ubi3 promoter/intron and upstream of the Act2 IntronL. For this purpose a 719 bp Nhel/SacII ZYMV CP non-translated fragment is isolated from pZU613 and cloned in the Nhel and SacII sites of pZU616. The construct is designated pZU617. Subsequently a PRSV CP non-translated fragment is cloned into pZU617 downstream of the Ubi3 promoter/intron and upstream of the ZYMV CP non-translated fragment. For this purpose a 720 bp BamHI/Nhel PRSV CP non-translated fragment is isolated from pZU612 and cloned in the BamHI and Nhel sites of pZU617. This new construct is named pZU618.

The last fragment to be cloned to complete the gene cassette contains a PRSV CP non-translated fragment and downstream thereof a ZYMV CP non-translated fragment in the same orientation. A corresponding fragment is amplified from pZU618 as template using Pfx PCR and the primers ZUP1565 and ZUP1568. The PCR fragment is cloned into the EcoRV site of pBluescript SK+ and the resulting plasmid is named pZU619.

To create an inverted repeat gene cassette the PRSV CP (nt) / ZYMV CP (nt) fragment is inserted in pZU618 in opposite direction of the PRSV CP (nt) / ZYMV CP (nt) fragments already present in the pZU618 plasmid. For this purpose a 1445 bp Sall/Ncol PRSV CP (nt) / ZYMV CP (nt) fragment is isolated from pZU619 and cloned in pZU618 digested with Sall and Ncol downstream of the Act2 IntronL and upstream of the NOS terminator. The resulting plasmid is designated pZU622. Said cassette is inserted into the binary vector pZU547, a binary vector derived from the plasmid pVictorHink additionally containing a SMAS promoter / PMI / NOS terminator selection cassette. To this end the 5414 bp Ascl/Pacl DNA fragment containing the inverted repeat gene cassette is isolated from pZU622 and cloned into the Ascl and Pacl sites of pZU547 in tandem orientation and upstream of the selection cassette. The final construct is designated pZU623 (SEQ ID NO: 25).

**Example 11: Construction of a plant transformation vector for Potato Virus Y (PVY) resistance in Tomato**

Based on the sequence of PVYn (a French field isolate of PVY), published in the thesis 'Engineering resistance against potato virus Y' of R.A.A. van der Vlugt (1993), two primers (ZUP1598: 5' -CATGCCATGGATCCAATGGCCACGAATTAAAGCTATCACGTC-3' - SEQ ID NO: 26, and ZUP1590: 5' -ACGCGTCGACCGCGGATTCAAACGATTATTAATTACGATAAAAG-3' -

SEQ ID NO: 27) are used to amplify by standard PCR techniques using Platinum Pfx DNA polymerase from Life Technologies a 804 bp fragment containing the coat protein cistron sequences and 99 nucleotides of the 3'-end non-translated region. The amplified PCR fragment is cloned as a blunt end fragment in the EcoRV site of pBluescript SK+ the plasmid being designated pZUA. The amplified PVY specific insert is excised from as a BamHI/SacII fragment and cloned into the BamHI/SacII sites of pZU616 (see example 10), yielding pZUB. pZUB and pZUA are both digested with Ncol and Sall. The PVY specific fragment from pZUA is purified from agarose gel and ligated into the pZUB digested with Ncol and Sall, yielding pZUC containing the following elements:

The UBI3 promoter with intron followed by the PVY PCR product in sense orientation as a BamHI/SacII fragment, followed by a SacII/Sall ACT2 intron, followed by the PVY PCR product in antisense orientation as a Sall/Ncol fragment and finally a nos terminator as a Ncol/HindIII fragment. Finally, pZUC is cloned into the binary vector pZU547 containing the SMAS promoter / PMI / NOS terminator selection cassette derived from the pHINK 085 binary vector. The final construct is designated pZU634 (SEQ ID NO: 28).

#### **Example 12: Transformation of binary vectors to melon and tomato plant material**

Methods to transfer binary vectors to plant material are well established and known to a person skilled in the art. Variations in the procedures are due to, for instance, differences in *Agrobacterium* strains used, different sources of explant material, differences between the regeneration systems, as well as different cultivars of the plant species to be transformed. The binary plant transformation vectors described in examples 10 and 11 above are used in transformation experiments according to the following procedures. The binary vectors are transferred to *Agrobacterium tumefaciens* by electroporation, followed by inoculation and cocultivation of plant explant material with the transformed *Agrobacterium* strain, selective killing of the *Agrobacterium* strain using an appropriate antibiotic, selection of transformed cells by growing on selective media containing mannose, transfer of tissue to shoot inducing media, transfer of selected shoots to root inducing media, and transfer of plantlets to soil. To confirm the presence of the gene cassettes described in examples 10 and 11 above, total DNA from the transgenic plants is characterized using well known Southern Blot Analysis techniques.

**Example 13: Screening transgenic melon plants for ZYMV and PRSV resistance**

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. Primary transformants are self pollinated and seeds harvested.

100 plants of the S1 progeny of the primary transformants are analyzed for segregation of the inserted gene and subsequently infected with ZYMV by mechanical inoculation. Tissue from host plants systemically infected with ZYMV is ground in 5 volumes of ice cold inoculation buffer (10mM phosphate buffer) and rubbed in the presence of carborundum powder on the cotelydons and first leave of 1 week old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation. Plants containing ZYMV sequences show reduced susceptibility to ZYMV infection compared with untransformed control plants which show severe systemic ZYMV symptoms within 7 days after inoculation. ZYMV tolerant plants are self pollinated and seeds harvested. Transgenic ZYMV resistant plants are mechanically inoculated with PRSV according to the procedures described above. Plants already resistant to ZYMV also show reduced susceptibility to PRSV infection compared with untransformed control plants which show severe systemic PRSV symptoms within 7 days after inoculation.

**Example 14: Screening of transgenic tomato plants for resistance against PVY**

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by pathogens. Primary transformants are self pollinated and seeds harvested.

50 plants of the S1 progeny of the primary transformants are analyzed for segregation of the inserted gene and subsequently infected with PVY by mechanical inoculation. Tissue from host plants systemically infected with PVY is ground in 5 volumes of ice cold inoculation buffer (10mM phosphate buffer) and rubbed in the presence of carborundum powder on the first two fully extended leaves of 5 weeks old seedlings. Inoculated plants are monitored for symptom development during 3 weeks after inoculation. Plants containing PVY sequences show reduced susceptibility to PVY infection compared with untransformed control plants which show severe systemic PVY symptoms within 7 days after inoculation.

The above disclosed embodiments are illustrative. This disclosure of the invention will place one skilled in the art in possession of many variations of the invention. All such obvious and foreseeable variations are intended to be encompassed by the appended claims.

***What is claimed is:***

1. A method of altering the expression of a viral genome comprising introducing into a cell a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
2. The method of claim 1 rendering said cell virus resistant or tolerant.
3. The method of claim 1, wherein said cell is a plant cell.
4. The method of claim 1, wherein said virus is selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses.
5. The method of claim 1, wherein said DNA sequences comprises a nucleotide sequence derived from a viral coat protein gene, a viral nucleocapsid protein gene, a viral replicase gene, or a viral movement protein gene.
6. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are stably integrated in the genome of said cell.
7. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are comprised in two separate DNA molecules.
8. The method of claim 1, wherein at least two pairs of first and second DNA sequences are introduced into a cell.
9. The method of claim 8, wherein each pair of DNA sequences encodes sense and antisense RNA fragments of different virus species or isolates.
10. The method of claim 1, wherein said first DNA sequence and said second DNA sequence are comprised in one DNA molecule.
11. The method of claim 10, wherein said first DNA sequence and said second DNA sequence are comprised in the same DNA strand of said DNA molecule.
12. The method of claim 11, wherein said sense RNA fragment and said antisense RNA fragment are comprised in one RNA molecule.

13. The method of claim 12, wherein said RNA molecule is capable of folding such that said RNA fragments comprised therein form a double-stranded region.
14. The method of claim 1, wherein the expressed RNA molecule comprises the inverted repeat sequence of SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 25 or SEQ ID NO: 28.
15. The method of claim 24, wherein expression of said RNA molecule is driven by a heterologous, a tissue-specific, a developmentally regulated, a constitutive, or an inducible promoter.
16. The method of claim 15, wherein expression of said RNA molecule is driven by a ubiquitin promoter such as the *Arabidopsis Ubi3* promoter.
17. The method of claim 15, wherein expression of said RNA molecule is driven by the *Agrobacterium rolC* promoter.
18. The method of claim 12, wherein said DNA molecule comprises a linker between the DNA sequences encoding said sense RNA fragment and said antisense RNA fragments.
19. The method of claim 18, wherein the linker is defined by the nucleotide sequence of the leader intron of the *Arabidopsis Actin 2* gene.
20. The method of claim 18, wherein the linker is defined by a nucleotide sequence of the viral region flanking the sense or antisense RNA fragment.
21. The method of claim 18, wherein said linker comprises an expression cassette of a functional gene such as a selectable marker gene.
22. The method of claim 21, wherein said linker comprises regulatory sequences such as intron processing signals.
23. The method of claim 11, wherein said sense RNA fragment and said antisense RNA fragment are comprised in two separate RNA molecules.
24. The method of claim 23, wherein said first DNA sequence and said second DNA sequence are operably linked to a bi-directional promoter.
25. The method of claim 11, wherein said first DNA sequence and said second DNA sequence are comprised in complementary strands of said DNA molecule.

26. The method of claim 25, wherein said first DNA sequence is the complementary DNA strand of said second DNA sequence in said DNA molecule.
27. A DNA construct altering the expression of a viral genome comprising a first DNA sequence capable of expressing in a cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming a double-stranded RNA molecule.
28. The DNA construct of claim 27, wherein said DNA construct comprises a first promoter operably linked to said first DNA sequence and a second promoter operably linked to said second DNA sequence.
29. The DNA construct of claim 27, wherein said DNA construct comprises a bi-directional promoter operably linked to said first DNA sequence and to said second DNA sequence.
30. A cell showing altered expression of a viral genome comprising a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
31. A plant and the progeny thereof derived showing altered expression of a viral genome comprising a first DNA sequence capable of expressing in said cell a sense RNA fragment of said viral genome and a second DNA sequence capable of expressing in said cell an antisense RNA fragment of said viral genome, wherein said sense RNA fragment and said antisense RNA fragment are capable of forming double-stranded RNA.
32. The plant of claim 31, wherein said plant is virus resistant or tolerant.
33. Seeds derived from the plant of claim 31.

## SEQUENCE LISTING

<110> Novartis AG

<120> Regulation of Viral Gene Expression

<130> S-30959A

<140>

<141>

<150> US 09/309038

<151> 1999-05-10

<160> 28

<170> PatentIn Ver. 2.1

<210> 1

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds\_Luc1

<400> 1

cgcggatcct ggaagacgcc aaaaaca

27

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds\_Luc2

<400> 2

cggaagctta ggctcgccata atcgcagtat ccggaatg

38

<210> 3

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ds\_Luc3

<400> 3

cggtagatgg gaagacgcca aaaacata

28

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: JG-L

<400> 4

gtacctcgag tctagactcg ag

22

<210> 5

<211> 4732

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pVictorHINK

<400> 5

gcacgaaccc cccgttcagc ccgaccgctg cgccattatcc ggtaactatc gtcttgagt 60  
caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggatttagcag 120  
agcgaggat tatcgccact gtcacagat ttgttgcgg tggcttaact acggctacac 180  
tagaaggaca gtatggta tctgcgtct gctgaagcca gttacccctg gaaaaagagt 240  
tggtagctct tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa 300  
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttatct ttctacggg 360  
gtctgacgct cagtgaaacg aaaactcacg ttaaggatt ttgttcatga gattatcaa 420  
aagatcttc acctagatcc ttttgcgtt gattaattt ctgtgggtt catgcacata 480  
caaatggacg aacggataaa ccttttcacg ccctttttaaa tatccgatta ttctaaataaa 540  
cgctctttc ttcttaggtt acccgccaat atatcctgtc aaacactgtat agtttaaact 600  
gaaggcggga aacgacaatc tgatcatgag cggagaattt agggagtcac gttatgaccc 660  
ccggcgtatga cgcgggacaa gccgttttac gtttggaaact gacagaaccc caacgctgca 720  
ggaattggcc gcagcggcca tttaatcaa ttggcgcgc cgaattcggat ctcggtagcc 780  
ggggatcctc tagagtcgac catgggtatc actgcaggca tgcaagctt gtagttaat 840  
taattcgaat ccggagcggc cgacacgttgc ggcccgttta aacctcgaga gatctgttag 900  
ccctgcagga aatttacccg tgccggcgc gccagcatgg ccgtatccgc aatgtgttat 960  
taagttgtct aagcgtcaat ttgttacac cacaatataat cctgccccca gcccggccaa 1020  
agctccccga ccggcgttgc ggcacaaaat caccactcgat tacaggcagc ccatcagaat 1080  
taattctcat gtttgcacgc ttatcatcgat ctgcacgggtt caccatgtat ctcgggttca 1140  
ggcagccatc ggaagctgtt gtatggctgtt gcaaggctgtt aatcactgca taattctgtt 1200  
cgctcaaggc gcactcccgt tctggataat gtttttgcgc cgcacatcat aacgggttctg 1260  
gcaaatattt tggaaatggac tggataat taatcatcgat ctcgtataat gtttggaaatt 1320  
gtgagcggat aacaatttca cacagggaaac agaccatgtt ggaagcgggtt atcgccgaag 1380  
tacatcgactca actatcagag ttagttggcg tcacatcgatcc ccacatctcgaa ccgcacgttgc 1440  
tggccgtaca ttgttacggc tccgcgttgc atggcggccct gaagccacac agtgatattt 1500  
atttgctgtt tacgggttgc gtaaggctt atgaaacaac gcccggagct ttgttcatcgat 1560  
accttttggaa aacttcggct tccctggag agagcggatcc tccctggctt gtagaagtca 1620  
ccatttgttgc gcaacgcac atcattccgtt ggcgttatcc agctaagcgc gaactgcaat 1680  
ttggagaatg gcaacgcac atcattccgtt caggatctt ccgcacatcat aacgggttctg 1740  
ttgttcatcgat ttttgcgttgc acaaaaatggac gagaacatcgat cttgcgttgc gtaggtccag 1800  
ccggcggagga aacttttgc gcaacgcac atcattccgtt ggcgttatcc agctaagcgc gaactgcaat 1860  
ccttaacgc atgaaactcg ccgcggact gggctggcgtt gtagaagtca 1920  
cggttcccg cattttggatc agcgcgttgc ccggcggactt ccgcacatcat aacgggttctg 1980  
ccgactgggc aatggcggcgc ctgcggccccc agtacatcgat cttgcgttgc gtaggtccag 2040  
aggcttgcgttgc tggacaagaa gatcgcttgc ctcgcgcgc agatcgttgc gtaggtccag 2100  
ttcactacgt gaaaggcggatc acaccaagg tagtccggcaa ataaagctt gtaggtccag 2160  
cgaggaatcg gcaacgcac atcattccgtt ggcgttatcc agctaagcgc gaactgcaat 2220

gtatgacccgtgggagaag ttgaaggccc cgcaaggccgc ccagcggcaa cgcatcgagg 2280  
 cagaagcacgc ccccggtgaa tcgtggcaag cggccgtcg tgaatccgc aaagaatccc 2340  
 ggcaaccgc ggcagccgt ggcgtcg ttaggaagcc gcccaaggc gacgagacaac 2400  
 cagattttt cgttcccgatg ctctatgacg tggcacccg cgatagtcgc agcatcatgg 2460  
 acgtggccgt tttccgtcg tgaagcgtg accgacgagc tggcaggtg atccgctacg 2520  
 agcttccaga cgggcacgtg gaggtttcag cagggccggc cggcatggc agtgtgtggg 2580  
 attacgacct ggtactgtatgcggtttccc atctaaccga atccatgaac cgataccggg 2640  
 aagggaaggg agacaagccc ggcgcgtgt tccgtccaca cggtgcggac gtactcaagt 2700  
 tctgcggcg agccgtggc gaaaagcaga aagacgaccc ggtagaaacc tgcatcggt 2760  
 taaaacaccac gcacgttgcc atgcagcgtg cgaagaaggc caagaacggc cgcctggta 2820  
 cggtatccga gggtaagcc ttgattagcc gctacaagat cgtaaagagc gaaaccggc 2880  
 ggccggagta catcgagatc gagctagctg attggatgtt cgcgcgatc acagaaggca 2940  
 agaaccggc cgtgctgacg gttcaccccg attactttt gatcgatccc ggcatcgcc 3000  
 gtttctcta ccgcctggca cggcgcggc caggcaaggc agaagccaga tggttgttca 3060  
 agacgatcta cgaacgcgtt ggcagcggc gagagtcaa gaagttctgt ttcacccgtc 3120  
 gcaagctgat cgggtcaaat gacctgccc agtacgattt gaaggaggag gggggcagg 3180  
 ctggcccgat cctagtcatg cgctaccgc acctgatcgaa gggcgaagca tccgcgggtt 3240  
 cctaattgtac ggagcagatg cttagggcaaa ttggccctagc agggggaaaaa ggtcgaaaaag 3300  
 gtctcttcc tgtggatagc actacattt ggaaccaaaa ggcgtacattt gggAACCGGA 3360  
 aacccgtacat tgggaacccca aagccgtaca ttgggaaccg gtcacacatg taagtgactg 3420  
 atataaaaga gaaaaaaggc gatccccccg cctaaaactc tttaaaactt attaaaactc 3480  
 ttaaaacccg cctggcctgt gcataactgt ctggccagcg cacagccgaa gagctgcaaa 3540  
 aagccctac cttcggtcg ctgcgtccc tacccccgc cgcttcgcgt cggcctatcg 3600  
 cggccgctgg cgcgtcaaaa atggctggcc tacggccagg caatctacca gggcgcggc 3660  
 aagccgcgc gtcgccactc gaccggcggc gctgaggtct gcctcgtgaa gaaggtgtt 3720  
 ctgactcata ccaggcctga atcgccccat catccagcca gaaagtgagg gagccacgg 3780  
 tgatgagacg tttgtttagt gtggaccagt tgggtatccc gaaacttttc tttgccacgg 3840  
 aacggcttcgc gttgtcggga agatgcgtga tctgatccctt caactcagca aaagttcgat 3900  
 ttattcaaca aagccggcg cccgtcaagt cagcgtatg ctctgcccgt gttacaacca 3960  
 attaaccat tctgattaga aaaactcatc gagcataaa tgaactgca atttattccat 4020  
 atcaggattt tcaataccat attttggaaa aagccgttc tgtaatgaag gagaaaaactc 4080  
 accgaggcag ttccatagga tgcaagatc ctggatcg tctgcgattc cgactcgatc 4140  
 aacatcaata caacctatta atttccccctc gtcaaaaata agttatcaa gtgagaaatc 4200  
 accatgagtg acgactgaat ccggtgagaa tggcaaaagc tctgcattaa tgaatcgcc 4260  
 aacgcgcggg gagaggcggt ttgcgtattt ggcgccttc cgcttcctcg ctcaactgact 4320  
 cgctgcgtc ggtcggtccgg ctgcggcgag cggtatcagc tcactcaaaag gcggtaaatac 4380  
 ggttatccac agaattcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa 4440  
 aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cgccccctcg 4500  
 acgagcatca caaaaatcgca cgctcaagtc agaggtggcg aaacccgaca ggactataaa 4560  
 gataccaggc gttccccctt ggaagctccc tcgtgcgtc tcctgttccg accctgcgc 4620  
 ttaccggata cctgtccgccc ttctccctt cgggaagcgt gggcgttttcaatgctcac 4680  
 gctgttagtgc tctcagttcg gtgttagtgc ttcgtccaa gctggctgt gt 4732

&lt;210&gt; 6

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: HiNK025bis

&lt;400&gt; 6

caattaccat ggacacggtc gtgg

24

<210> 7  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK226

<400> 7  
gccaaatgtt tgaacgctgc agcctatttg

30

<210> 8  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK025bis2

<400> 8  
aatcgccat ggatacggtc gtgg

24

<210> 9  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK226bis

<400> 9  
ctagggccgg gttcctctgc agcctatttg

30

<210> 10  
<211> 31  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK251

<400> 10  
ctcccagggtt gagactgcccc tgcagtgccca a

31

<210> 11  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK228

<400> 11  
ttaccatgca tacggtcgtg ggtagg

26

<210> 12  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HiNK228bis

<400> 12  
cgtaatgca tacggtcgtg ggtagg

26

<210> 13  
<211> 3338  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: BWYV duplex  
RNA gene

<220>  
<221> promoter  
<222> (1)..(1131)  
<223> RolC promoter

<220>  
<221> repeat\_unit  
<222> (1132)..(1737)  
<223> BWYV CP inverted repeat fragment

<220>  
<221> stem\_loop  
<222> (1738)..(2470)  
<223> 0.7 Kb spacer fragment downstream of BWYV CP gene

<220>  
<221> repeat\_unit  
<222> (2471)..(3074)  
<223> BWYV CP inverted repeat fragment

<220>  
<221> terminator  
<222> (3076)..(3338)  
<223> NOS terminator

<400> 13  
ggatccggcg tcggaaactg gcgc当地 aacacagtct ctggcggga aagccagagg 60  
tagtttggca acaatcacat caagatcgat gc当地 agaca cggaggcct taaaatctgg 120  
atcaagcgaa aatactgc当地 gctgtatcgat tcatgggatc atagtaatgg gtttgcttt 180  
tcttgc当地 gtg ttgtttggcc tt当地 agcgaaag gatgtcaaaa aaggatgcc ataattggga 240  
ggagtgggggt aaagctaaa gttggccgc tattggatt cg当地 gaaagcg cattggcaaa 300

cgtgaagatt gctgcattca agatacttt tctatatttct ggtaaagatg . taaagtattg 360  
ccacaatcat attaattact aacattgtat atgtaatata gtgcggaaat tatctatgcc 420  
aaaatgatgt attaataata gcaataataa tatgtgttaa tcttttcaa tcggaatac 480  
gtttaagcga ttatcggtt gaataaaatta ttccaaaagg aaatacatgg ttttgagaa 540  
cctgtatag atatatgcca aatttacact agtttagtgg gtgc当地act attatctctg 600  
tttctgagtt taataaaaaaa taaataagca gggcgaatag cagttagcct aagaaggaat 660  
ggtggccatg tacgtgttt taagagaccc tataataaaat tgccagctgt gttgtttgg 720  
tgccgacagg cctaacgtgg gtttagtt gacaaagtag cgcccttccg cagcataaat 780  
aaaggttaggc gggtgctcc cattattaaa ggaqaaagca aaagctgaga ttccatagac 840  
cacaaccac cattattgga ggacagaacc tattccctca cgtgggtcgc tgagctttaa 900  
acctaataag taaaacaat taaaagcagg caggtgtccc ttctatattc gcacaacgag 960  
gcgacgtgga gcatcgacag ccgcattccat taattaataa atttgtggac ctatacctaa 1020  
ctcaaattatt ttatttattt gctccaatac gctaagagct ctggattata aatagtttg 1080  
atgcttcgag ttatgggtac aagcaacctg tttctactt tgtaaccatg gacacggcgtc 1140  
tggtaggag aattatcaat ggaagaagac gaccacgcag gcaaacacga cgcgctcage 1200  
gccctcagcc agtgggtgtg gtccaaacct ctccggcaac acaacgcccga cctagacgac 1260  
gacgaagagg taacaaccgg acaggaagaa ctgttccctac cagaggagca gttcgagcg 1320  
agacatttgt ttctcaaaa gacaatctcg cgggaagtgc cagcggagca atcacgttcg 1380  
ggccgagtcg atcagactgc ccggcattct ctaatggaaat gctcaaggcc taccatgagt 1440  
ataaaatctc aatggtcatt ttggagttcg tctccgaagc ctctcccaa aattccygtt 1500  
ccatcgctta cgagctggac ccacactgta aactcaactc ccttccctca actatcaaca 1560  
agttcgggat cacaagccc gggaaaaggcg cgttacagc gtcttacatc aacgaaacgg 1620  
aatggcacga cgttgcccgag gaccaattca ggatccctca caaaggcaat gtttttcat 1680  
cgatagctgg ttcttcaga atcaccatttta agtgcatttcc cacaaccccc aaataggctg 1740  
cagtgcccaa ctctcttgg tctttctgtc ttacggaaac cggatgagcc ttgttcatca 1800  
agtgctatgg cgatcatccc tatctccatc atccgatctg tccaggctcc gtacgaaacg 1860  
gcgttaattat atttagatttgc ttcttgacca gcccgtccaa caacaagaaa ggaggcatttgc 1920  
tcaccagtcg tcttgatatg acaagtcaaa tctccatctc tttccagaca ctgtccttga 1980  
ttgaaatgac agcatttggat ttccatgtct gggtgccat acttcaaagt attatcgcc 2040  
ttgttgggttgg ttatctccac attattgtaa atccccacgt tccaaccttc actaagatca 2100  
tgcgtttagg cgatgagacc atctgttttgc tcctgttag gatctgtggt gcttgagggtt 2160  
ggttgatacc cctccatcgat tatttccacg gtccactcac ctggagggac tggcactatt 2220  
atcatcgggta tggctttcaa agaattctgg gaataccatc gagaatcgag gttcgccag 2280  
ttcatgttct cgttctctat gtagcgaaac cgttggacg gcatatcata caaagagatg 2340  
gcatcatccg tagattgagc cattatacga gtcacgggaa ctccagttata gacgataaaa 2400  
cgatatttct tttgggggtgt ggggtgttgg gagggagaag gcccggcttggc agggccgggt 2460  
tcctcgctca cctattttgg gttgtggaaat tgacacttta tggtgatttct gaaagaacca 2520  
gctatcgatg aagaaccatt gcctttgttag aggatcctga attggtcctc ggcaacgtcg 2580  
tgccattccg ttccgttgc gtaagacgt gtaaacgccc ttttccggg ctttgtgatc 2640  
ccgaacttgc tgatagttga ggaaaggagg ttgagtttac agtgtgggtc cagctcgtaa 2700  
gogatggAAC cgaaatttttgc ggaagaggct tcggagacga actccaaat gaccatttgg 2760  
attttataact catggtaggc ttgagcatt ccattagaga atgcccggca gtcgtataga 2820  
ctcgccccga acgtgatttgc tccgctgaa cttcccgca gattgtctt tgagaaaaca 2880  
aatgtctcgc tcgaacctgc ttctctgtt ggaacagttc ttccgttccg gttgttacct 2940  
cttcgtcgat gtcgttgc ggttgttgg gcccggagg tttggaccac aaccactggc 3000  
tgagggcgat gaggcgctcg tgggttgc tgggttgc ttttccatt gataattctc 3060  
ctacccacga ccgtatgcag atcgatcaaa catttggcaaa taaagtttct taagattgaa 3120  
tcctgttgc ggttgc gtaattatcat ataatttctg ttgaatttacg ttaagcatgt 3180  
aataattaac atgatatttgc tgacgttatt tatgagatgg gtttttatgaa ttagatccc 3240  
gcaatttatac attaataacg cgatagaaaaaaa caaatatag cgccaaacctt aggataaaatt 3300  
atcgccgcgat gttcatctat gtttactaga tctcttgc 3338

<210> 14  
<211> 29  
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK285

<400> 14

tgcgtagaaga gaattcaccc aaactatcc

29

<210> 15

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK283

<400> 15

aagaattgca ggatccacag gctcggtac

29

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HiNK284

<400> 16

ttccaacgaa ttccgtctca gaca

24

<210> 17

<211> 3648

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: pHINK181

<220>

<221> promoter

<222> (1)..(1738)

<223> ubiquitin 3 promoter plus intron

<220>

<221> repeat\_unit

<222> (1739)..(2166)

<223> ENYVV RNA1 repeat fragment

<220>

<221> misc\_feature

<222> (2167)..(2946)

<223> spacer fragment



taaaacagctg ggtctttggg aagatttta atccaatcac gcaaagattc ctggtattca 2400  
 caaaaatgct tataactcacg gaacctgtgt gctgctatct tcgtcaattt' acgcgaaaca 2460  
 cttggaaaca aatgtccatt agataaagca taaccacaaa aagtgatagg aacatttaaa 2520  
 tccaatttga aatccaagac agtttcctt ttaatcaact ttaacatttgc atcgtaatt 2580  
 ttcaaatttag cctgcctttt aaaaccatca tcgcccattca tggccatata. aaatggtccg 2640  
 gtcacacgaa gcataggcatt taacatagca cccattaaaaa tggtattacc aagcaaagtg 2700  
 ccgggttctc cactagtctt aacataagac atatgtgctc tgacatatct ggactgcata 2760  
 acatatttct cacgaaatga gaaataccaa tccaaaaaga agtcagaaaat gccccaaagca 2820  
 gcataaataat gtctttctat caattgggtg aaaaccctt gcccagaatc gcaaggcagca 2880  
 gcatcgataa ccccgtttat agcactatct ggtatcttat tcattggcggc atttattttt 2940  
 ccaacaaaattt cggtctcaga cattgtgtta tcgtaaacaa cattagaggtaatgacttc 3000  
 aataacaaaat tattaaaac tctaaaagca accataaaact taacatgtgc ctccttagac 3060  
 catgccaata tcccttgacc agccttgcc aaatcagtct ctgggtcattt caaagggtttt 3120  
 tcaatatcct tcaactgaaa acgatatagtt tagcattac gctaaactc ctcttccatt 3180  
 tggccttggg aatttttgc gaccatgtca tgcatagctt tgccataat tcgcccacaaa 3240  
 - ttggaagcag aaaaagtatc agtacatctt ggcacccaaac aatcagaaaac aaatagctga 3300  
 gcaaccatac gtgcaacact atcttgcgtc gatgatggag aatttctcac ttttcgaaat 3360  
 aagtaccgag cctgtgatc ccccgatcgt tcaacacattt ggcaataaag 3420  
 tttcttaaga ttgaatctt tgccggctc tgcgtatgatt atcatctaatttctgttcaa 3480  
 - ttcacgttaag catgtataaa ttaacatgtatc atgcgtatc ttatattgtatc gatgggtttt 3540  
 tatgatttgc gtcggcaat tatacatttatacgtatc gaaaacaaaaa tatagcgcgc 3600  
 aaacttaggtt aaattatcgc ggcgggtgtc atctatgtta ctatgtcc 3648

<210> 18  
 <211> 3648  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: pHINK184

<220>  
 <221> promoter  
 <222> (1)..(1738)  
 <223> ubiquitin 3 promoter plus leader intron

<220>  
 <221> repeat\_unit  
 <222> (1739)..(2166)  
 <223> BNYVV RNA1 repeat fragment

<220>  
 <221> misc\_feature  
 <222> (2167)..(2946)  
 <223> spacer

<220>  
 <221> repeat\_unit  
 <222> Complement((2947)..(3375))  
 <223> BNYVV RNA1 repeat fragment

<220>  
 <221> stem\_loop  
 <222> (1739)..(3375)  
 <223> Inverted repeat of BNYVV RNA1 fragment separated

by spacer

<220>

<221> terminator

<222> (3376)..(3648)

<223> NOS terminator

<400> 18

ggtaccggat ttggagccaa gtctcataaa cgccattgtg gaagaaaagtc ttgagttgg 60  
 ggtaatgtaa cagagttaga agaacagaga agagagagag tggatgtac atgaattgtc 120  
 gggcaacaaa aatcctgaac atcttatttt agcaaagaga aagaggccg agtctgtac 180  
 agaagagtga ggagaaattt aagcttgg acttgtaat tggtccgcct cttgaataact 240  
 tcttcattcc tcataatattc ttcttctatg ttacctgaaa accggcattt aatctcgccg 300  
 gtttattccg gttcaacattt tttttgttt tgagttatta tctgggctta ataacgcagg 360  
 cctgaaataa attcaaggcc caactgtttt ttttttaag aagttgtgt taaaaaaaaaa 420  
 aaaagggaaat taacaacaac aacaaaaaaaaa gataaaagaaa ataataacaa ttacttaat 480  
 ttagactaa aaaaacatag attttatcat gaaaaaaaaa gaaaagaaaat aaaaacttg 540  
 atcaaaaaaaaaa aaaacataca gatcttctaa ttattaactt ttcttaaaaaa ttaggtcctt 600  
 tttcccaaca attaggtta gagtttggaa attaaaccaa aaagattgtt ctaaaaaaaaata 660  
 ctcaaatttg gtagataagt ttcccttattt taattgtca atggtagata cttttttttc 720  
 ttttctttat tagagtagat tagaatctt tatgccaagt tttgataat taaaatcaaga 780  
 agataaaacta tcataatcaa catgaaatta aaagaaaaat ctcatatata gtattgtat 840  
 tctctatata tattatgatt gcttatttctt aatgggtgg gttaaccaag acatagtctt 900  
 aatggaaaga atcttttttgc aacttttcc ttattgtatta aattttctta tagaaaaagaa 960  
 agaaattatt tgagggaaag tatataaaaaa aagaaaaataa gaaaaatgtc agtgaagcag 1020  
 atgtaatggc tgacctaattc caaccaccac cataggatgt ttctacttga gtcggcttt 1080  
 taaaaacgca cggtgaaaaa tatgacacgt atcatatgat tccttcctt agtttgcgt 1140  
 taataatcc tcactgtat cttccctttt ttgtttggc taaagatatt ttattctcat 1200  
 taatagaaaa gacggtttg ggctttggt ttgcgatata aagaagacct tcgtgtggaa 1260  
 gataataatt catccttcg tcttttctg actcttcaat ctctccaaa gcctaaagcg 1320  
 atctctgcaa atctctcgat actctcttca tcaaggataa ttttctgatt ctttttgcgtt 1380  
 ttgattcgta tctgatctcc aattttgtt atgtggatta ttgaatctt tggataat 1440  
 gctttgaca atattgtcg tttcgtaat ccagttctta aattttgtcc tgattactaa 1500  
 gatatcgatt cgtatgttt acatctgtgt aattttctgc ttgatgtga aatttaggatt 1560  
 ttcaaggacg atctattcaa tttttgtgtt ttctttgttc gattctctt gtttttaggtt 1620  
 tcttatgttt agatccgtt ctcttgggt ttgtttgtat ttctcttacg gcttttgatt 1680  
 tggatatgt tcgctgattt gttctactt gttctattgt ttatattcag gtggatccac 1740  
 aggctcggtt ctatattcga aaagtggaaa attctccatc atcgacacaa gatagtgtt 1800  
 cacgtatggt tgctcagta tttgtttctg attgtttgtt gccaaatgtc gctgataactt 1860  
 ttctcgcttc caatttggc cgaattatgg acaaagctat gcatgacatg gtcgcaaaaa 1920  
 attaccaagg ccaaatggaa gaggagttt cgcgtaatgc taaactatata cgttttcagt 1980  
 tgaaggatata tggaaaaaccc ttgaaggacc cagagactga ttggcaaaag gctggcaag 2040  
 ggatattggc atggctcaag gaggcacatg ttaagtttat ggttgccttt agagttttaa 2100  
 atgatttggt attgaagtca ttaaaactcta atgttggatcgataacaca atgtctgaga 2160  
 ccgaatttggt tggaaaaata aatgccgcca tgaatacagt accagatagt gctataaaacg 2220  
 gggttatcga tgctgctgt tgctgattctg ggcaagggtt tttcacccaa ttgatagaaa 2280  
 gacatattta tgctgcttg ggcatttctg acttctttt ggattgtat ttctcatttc 2340  
 gtgagaaata tggatgtcg tccagatgt tcagagcaca tatgtcttat gttaaagacta 2400  
 gtggagaacc cggcactttg cttggataata ccattttat gggtgctatg tttaaatgtca 2460  
 tgcttcgtgg gaccggacca tttttgtatgg ccatgaaggcgatgtatgg tttaaaaggc 2520  
 aggtaattt gaaaattaaac gatcaaattgt taaagttgtat taaaagggaa actgtcttgg 2580  
 atttcaattt ggatattaaat gttccatca ctttttggat ttatgttttcaatggac 2640  
 atttggccatc aagtgtttcg cgtaattga cgaagatagc agcacacagg ttccgtgat 2700  
 ataagcattt ttgtgaatac caggaatctt tgctgtatgg gattaaaaat ctccccaaag 2760  
 acccagctgtt ttagtgcgtat tttttggat gtaacgcgtat cttatcttgcgatgtt 2820  
 atgatgttca acgttgggtt gatgttattt tctctgtgtc tcgaatcgccg cgtgagcaat 2880

ttatgatgat gttcccgata cggaaagttt ttatgtcatt gccacccgtt gaggatagtt 2940  
 tgggtgaatt cggctcaga cattgtgtta tcgtaaacaa cattagagtt taatgacttc 3000  
 aataacaat cattaaaac tctaaaagca accataaaact taacatgtgc ctcccttagac 3060  
 catgccaata tcccttgacc agccttgcc aaatcagtct ctgggtcctt caaaggtttt 3120  
 tcaatatccct tcaactgaaa acgatatagt ttagcattac gctaaactc ctcttcatt 3180  
 tggccttggg aatttttgc gaccatgtca tgcatagctt tgtccataat tcgcccacaaa 3240  
 ttggaagcag aaaaagtatc agtacattt ggcaccaaac aatcagaaac aaatagctga 3300  
 gcaaccatac gtgcaacact atcttgcgtc gatgatggag aatttctcac ttttcgaaat 3360  
 aagtaccgag cctgtggatc ccccgaaattt ccccgatcgt tcaaacattt ggcaataaaag 3420  
 tttcttaaga ttgaatcctg ttgccggctc tgcgtatgatt atcatctaatttctgttcaa 3480  
 ttacgttaag catgtataaa ttaacatgtta atgcgtacg ttatttatga gatgggtttt 3540  
 tatgattaga gtcccgcaat tatacatttataacgacata gaaaacaaaa tatagcgcgc 3600  
 aaactaggat aaattatcgc ggcgggtgtc atctatgtta cttagatcc 3648

- <210> 19
- <211> 41
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: ZUP1563

<400> 19  
 gggcggatcc gctagccgc ggccgctctt tctttccaag g 41

- <210> 20
- <211> 35
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: ZUP1564

<400> 20  
 cccgccccatgg gtcgacgcca tttttatga gctgc 35

- <210> 21
- <211> 40
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: ZUP1565

<400> 21  
 cccgccccatgg gatccgatga tttctaccga gaattaaggg 40

- <210> 22
- <211> 29
- <212> DNA
- <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1566

<400> 22  
gggcgctagc ctaatgctta tatagtacc

29

<210> 23  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1567

- <400> 23  
gggcgctagc cttgctggag tataagccgg

30

<210> 24  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1568

<400> 24  
gggcgtcgac cgccggcttt aaaggtggga ggccc

35

<210> 25  
<211> 12766  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: pZU623

<220>  
<221> promoter  
<222> (55)..(1781)  
<223> ubiquitin3 promoter plus leader intron

<220>  
<221> misc\_feature  
<222> (1790)..(2430)  
<223> PRSV nt CP region

<220>  
<221> misc\_feature  
<222> (2511)..(3111)  
<223> ZYMV nt CP region

<220>  
<221> intron

<222> (3245)..(3686)  
<223> actin2 intronL

<220>  
<221> misc\_feature  
<222> Complement((3822)..(4422))  
<223> ZYMV nt CP region

<220>  
<221> misc\_feature  
<222> Complement((4503)..(5143))  
<223> PRSV nt CP region

<220>  
<221> terminator  
<222> (5160)..(5429)  
<223> NOS terminator

<220>  
<221> promoter  
<222> (5498)..(6669)  
<223> SMAS promoter

<220>  
<221> gene  
<222> (6691)..(7866)  
<223> phosphomannose isomerase A coding sequence

<220>  
<221> terminator  
<222> (7928)..(8202)  
<223> nopaline synthase terminator

<220>  
<221> misc\_feature  
<222> (8254)..(8385)  
<223> nopaline left border fragment

<220>  
<221> gene  
<222> (8664)..(9452)  
<223> spectinomycin (aadA) coding sequence

<220>  
<221> misc\_structure  
<222> (9462)..(11549)  
<223> pVS1 ORI

<220>  
<221> misc\_structure  
<222> (11550)..(12484)  
<223> pUC19 ORI

<220>  
<221> misc\_feature  
<222> (12500)..(12755)

<223> nopaline right border region

<220>

<221> stem\_loop

<222> (1790) .. (5143)

<223> PRSV-ZYMV inverted repeat fragment

<400> 25

ggccgcacgc gccattttaaa tcaattggc gcgcgcaatt cgagctcggtt accccggatt 60  
tggagccaag tctcataaaac gccattgtgg aagaaggact tgtagttgggt gtaatgtaac 120  
agagtagtaa gaacagagaa gagagagagt gtgagataca tgaattgtcg ggcaacaaaa 180  
atccctgaaca tcttattttt gcaaagagaa agagtcggc gtctgttagca gaagagttag 240  
gagaaattta agcttttgc cttgtgaatt gttccgcctc ttgaataactt cttcaatcct 300  
catatatattct tcttctatgt tacctgaaaaa ccggcattta atctcgccggg tttattccgg 360  
ttcaacatct tttttgtttt gagttattat ctgggcttaa taacgcaggc ctgaaataaa 420  
ttcaaggccc aactgtttt ttttaagaa gttgtgtta aaaaaaaaaa aagggatta 480  
acaacaacaa caaaaaaaga taaagaaaaat aataacaatt actttaattt tagactaaaa 540  
aaacatagat tttatcatga aaaaaagaga aaagaaataa aaacttggat caaaaaaaaa 600  
aacatacaga tcttotaatt attaacttt cttaaaaattt aggtcccttt tcccaacaat 660  
taggtttaga gttttggaaat taaacaaaaa agattgttctt aaaaaataact caaatttggt 720  
agataagttt ccttattttt attagtcaat ggtagataact tttttttctt ttctttatttt 780  
gagtagatta gaatttttt tgccaagtt tgataaatta aatcaagaag ataaactatc 840  
ataatcaaca tgaattttaa agaaaaatct catatatagtt attagtattt tcttatata 900  
ttatgatgc ttattcttaa tgggttgggt taaccaagac atagtcttaa tggaaagaat 960  
ctttttgaa cttttccctt attgattttt ttcttctata gaaaagaaaaa aatttttttg 1020  
aggaaaaagta tataaaaaaa gaaaaataga aaaatgtcag tgaagcagat gtaatggat 1080  
acctaatcca accaccacca taggtatgtt ctacttgagt cggctttta aaaaacgcacg 1140  
gtggaaaata tgacacgtat catatgattt cttcccttag tttcgtata ataatcctca 1200  
actgataatct tcctttttt gttttggcta aagatattttt attctcattt atagaaaaaga 1260  
cggttttggg cttttgggtt gcgtataaa gaagaccttc gtgtggaaaga taataattca 1320  
tcctttcgct ttttctgac tcttcaatct ctccccaaagc ctaaagcgtat ctctgcaaat 1380  
ctctcgac tctcttttc aaggatattt ttctgtattttt ttttggattttt gattcgtatc 1440  
tgatctccaa tttttgttat gtggattttt gaatctttt gataatttgc ttttgacaat 1500  
attgttcgtt tcgtcaatcc agcttctaaa ttttgcctgtt attactaaga tatcgattcg 1560  
tagtgttac atctgtttaa tttcttgctt gattgtaaa tttaggatttt caaggacgtat 1620  
ctattcaatt tttgtgtttt ctttggctca ttctctctgt ttttaggtttt ttatgttttag 1680  
atccgtttct ctttgggtgtt gttttgattt ctcttacggc ttttggattttt gtatatgttc 1740  
gctgatttgtt ttctacttgtt tcttattgtt tatttcaggt gggggatccg atgatttcta 1800  
ccgagaattta agggaaaagac tgccttaat taaaatcatc ttcttcaagta taatcccaa 1860  
caaattgaca tttctaacac tcgtgccact cagtcacaat ttgagaagtg gtatgaggga 1920  
gtgaggaatg attatggctt caatgataat gaaatgcag tgatgtctaa tggcttgatg 1980  
gtttgggtgtt tcgagaatgg tacatctcca gacatctgt gtgtctgggt tatgatggat 2040  
ggggaaaccc aagtgtttaa tccaatcaag ctttaatag agcatgctac tccgtcattt 2100  
aggcaattta tggctcactt tagtaacgcg gcagaagcat acattgcgaa gagaatgtct 2160  
actgagagat acatgcgcgc gtatggatc aagagaaatt tgactgacat tagtctgtct 2220  
agatacgctt tcgacttctt tgaggtgaat tcgaaaacac ctgatagggc tcgtgaagct 2280  
cacatgcaga tgaaagctgc agcgctcgaa aacactagtc gcagaatgtt tggtatggac 2340  
ggcagtgtta gtaacaagga agaaaaacacg gagagacaca cagtggaaaga tgtcaataga 2400  
gacatgcact ctctcctggg tatgcgcac tgaataactcg cgcttgggtt tttgtcgagt 2460  
ctgactcgac cctgtttcac cttatggatc tatataagca tttaggcttagc cttgctggag 2520  
tataagccgg atcaaattga gttatacaac acacgagctc ctcattcagca attcgctct 2580  
tggttcaacc aagttaaaac agaataatgtat ctgaatgagc aacagatggg agttgtatg 2640  
aatggttca tggttgggtt cattgaaaat ggcacgtcact cccgacattaa cggagttatgg 2700  
gttatgttgg acggtaatga gcagggttggaa ttttttttgc aaccaatagt tgaaaatgca 2760  
aagccaaacgc tgcgacaaat aatgcacatc ttttgcgtatc cagcggaggc atatatagag 2820  
atgagaaatg cagaggcacc atacatgcgcg aggtatgggtt tgcttcggaaa cttacqggat 2880

aggagtttgg cacgatatgc tttcgacttc tacgaagtca attccaaaac tccggaaaga 2940  
ggccgcgaag ctgtgcgc gatgaaagca gcagccctta gcaatgttc ttcaaggtg 3000  
tttggccttg atggaaatgt tgccaccact agcgaagaca ctgaacggca cactgcacgt 3060  
gatgttaata ggaacatgca caccttgcata ggtgtgaata caatgcagta aagggttagt 3120  
cgccctaccta ggttatcggt tcgctgccgta cgtaattcta atatttaccg ctttatgtga 3180  
tgtctttaga ttcttagagt gggcctccca cctttaaagc ccgcggccgc tctttcttc 3240  
caaggttaata ggaactttctt gcatctactt tatttgcgtt atctcgatct tgttttctca 3300  
atttccttga gatcttggaaat tcgtttaatt tggatctgtg aacctccact aaatctttt 3360  
gttttacttag aatcgatcta agttgaccga tcagttagct cgattatacg taccagaatt 3420  
tggcttgacc ttgtatggaga gatccatgtt catgttacct gggaaatgtatgt 3480  
gaatttgaat ctgaactgtt gaagtttagat tgaatctgaa cactgtcaat gtttagattga 3540  
atctgaacac tgtttaagtt agatgaagtt tttgtataga ttcttcgaaa ctttaggatt 3600  
tgttagtgcg tacgttgaac agaaagctat ttctgattca atcagggttt atttgactgt 3660  
attgaactct ttttgcgtgt ttgcagctca taaaaaatgg cgtcgaccgc gggctttaaa 3720  
ggtgggaggc ccactctaga aatctaaaga catcacataa agcggtaaat attagaatta 3780  
cgtcggcagc gaaaacgataa ccttaggttgg ctagtgcatttca aacaacccatc tttactgcatttca 3840  
ccttagcaagg tttgtgcatttca atcaaggccca aacaacccatc aagaaacatt gctaagggct 3900  
cttagtgcgttgg caacatttcc gctgtttca tctgcgcac tagaaagtgcg aagcatatcg 3960  
ctcggcatgt atgggtgcctc aagtgtatcgta ttccatatttca atcctctat atgcctccgc tgcatttca 4020  
aagtgtatcgta ttatttgcgtt cagcgttggc tttgcatttt caactattgg tttcaaagga 4080  
tattcaacactt gtcatttacc ccattttcaaa tgcacccatcttca aacaacccatc tttactgcatttca 4140  
ccattttcaaa tgcacccatcttca atccggcttca tactccagca aggctagctt aatgttata 4200  
agatcatatt ctgttttaac ttgggttgcgttccatccatcttca aacaacccatc tttactgcatttca 4260  
gtgttgtata actcaatttgcgtt tagtaccata aggtggaaaca cagttgcgcgta accccatcttca aacaacccatc tttactgcatttca 4320  
tagtaccata aggtggaaaca cagttgcgcgta accccatcttca aacaacccatc tttactgcatttca 4380  
ttccgtgtttt cttcttgcgtt actaacaactt ggtttttccatccatcttca aacaacccatc tttactgcatttca 4440  
tttcgcagcg ctgcagctt gatattttccatccatcttca aacaacccatc tttactgcatttca 4500  
gaaattttccatccatcttca aacaacccatc tttactgcatttca 4560  
tttgcgttccatccatcttca aacaacccatc tttactgcatttca 4620  
tttcgcagcg ctgcagctt gatattttccatccatcttca aacaacccatc tttactgcatttca 4680  
gaaatccatccatcttca aacaacccatc tttactgcatttca 4740  
tttgcgttccatccatcttca aacaacccatc tttactgcatttca 4800  
gcccgcgttccatccatcttca aacaacccatc tttactgcatttca 4860  
ggcttgcgttccatccatcttca aacaacccatc tttactgcatttca 4920  
tctggagatg taccatttccatccatcttca aacaacccatc tttactgcatttca 4980  
tcattatcat tgagaccata aatgttccatccatcttca aacaacccatc tttactgcatttca 5040  
tgagtggcac gagggtttaga aatgttccatccatcttca aacaacccatc tttactgcatttca 5100  
aaattaaagga cagtcttccatccatcttca aacaacccatc tttactgcatttca 5160  
tgcagatcgatccatccatcttca aacaacccatc tttactgcatttca 5220  
tgcgttccatccatcttca aacaacccatc tttactgcatttca 5280  
atgcgttccatccatcttca aacaacccatc tttactgcatttca 5340  
atacgcgttccatccatcttca aacaacccatc tttactgcatttca 5400  
atctatgttccatccatcttca aacaacccatc tttactgcatttca 5460  
cgccaggccatccatcttca aacaacccatc tttactgcatttca 5520  
cgatccatccatcttca aacaacccatc tttactgcatttca 5580  
tccatcttgcgttccatccatcttca aacaacccatc tttactgcatttca 5640  
gtaagcgctt acgttccatccatcttca aacaacccatc tttactgcatttca 5700  
tcgctttccatccatcttca aacaacccatc tttactgcatttca 5760  
tcttagccgttccatccatcttca aacaacccatc tttactgcatttca 5820  
ttaatgttccatccatcttca aacaacccatc tttactgcatttca 5880  
caaaaacgttccatccatcttca aacaacccatc tttactgcatttca 5940  
tccaacgttccatccatcttca aacaacccatc tttactgcatttca 6000  
aatttcgttccatccatcttca aacaacccatc tttactgcatttca 6060  
tggaaatttccatccatcttca aacaacccatc tttactgcatttca 6120  
gtccaccatccatccatcttca aacaacccatc tttactgcatttca 6180  
ttaacatccatccatcttca aacaacccatc tttactgcatttca 6240

cattgcttt gaaggcagctc aacattgtatc tctttctcgaa gggagatccc tcaaatacg 6300  
 gcgcgaagacg tgacgtaagt atccgagtca gtttttattt ttctactaat ttggtcgtt 6360  
 atttcggcgt gtaggacatg gcaaccggc ctgaatttcg cgggtattct gtttctattc 6420  
 caacttttc ttgatccgca gccattaacg acttttgaat agatacgtcg acacgccaag 6480  
 cctcgctagt caaaagtgtt ccaaacaacg ctttacagca agaacggat ggcgtgtacg 6540  
 ctcgcgtga cgccatttcg cttttcaga aatggataaa tagccttgct tcctattata 6600  
 tcttccaaa ttaccaatac attacactag catctgaatt tcataaccaa tctcgataca 6660  
 ccaaatacgag atctgcaggg atccccgatc atgaaaaac tcattaactc agtgcaaaaac 6720  
 tatgcctggg gcagcaaaaac ggcgttgact gaactttatg gtatggaaaa tccgtccagc 6780  
 cagccgatgg ccgagctgtg gatggcgca catccgaaaa gcagttcacg agtgcagaat 6840  
 gcccggag atatcgttt actgcgtgtat gtgattgaga gtgataaaatc gactctgctc 6900  
 ggagaggccg ttgccaaacg ctttggcga ctgcctttcc tggtaaagt attatgcgc 6960  
 gcacagccac tctccattca gttcatcca aacaaacaca attctgaaat cggtttgccc 7020  
 aaagaaaatg ccgcaggat cccgatggat gccgcccggc gtaactataa agatcctaac 7080  
 cacaagccgg agctggttt tgcgtgtacg ctttccctt cgatgaacgc gttcgtgaa 7140  
 - tttccgaga ttgtctccct actccagccg gtcgcagggtg cacatccggc gattgctcac 7200  
 ttttacaac agcctgatgc cgaacgtttt aagcgaactgt tcgcccgcct gttgaatatg 7260  
 cagggtaag aaaaatcccg cgcgtggcg attttaaaat cggccctcgta tagccagcag 7320  
 ggtgaaccgt gcacaaacgat tegtttaatt tctgaattttt acccgaaaga cagcggtctg 7380  
 ttctccccgc tattgctgaa tggtaaccctg gcaagcgtat gttcctgttc 7440  
 gctgaaacac cgcacgctt cctgcaaggc gtggcgctgg aagtgtatggc aaactccgat 7500  
 aacgtgtgc gtgcgggtct gacgcctaaa tacattgata ttccgaaact gttgccaat 7560  
 gtgaaattcg aagccaaacc ggctaaaccag ttgttgcacc agccgggtaa acaaggtgca 7620  
 gaactggact tcccgattcc agtggatgat ttgccttcc cgctgatga ctttagtgat 7680  
 aaagaaaacca ccattagcca gcagagtgcc gccattttgt tctgctcgta aggcatgca 7740  
 acgttgcgaa aaggttctca gcagttacag cttaaaccgg gtgaatcagc gtttattgccc 7800  
 gccaacgaat caccgggtgac tgtcaaaggc cacggccgtt tagcgcgtgt ttacaacaag 7860  
 ctgtaaagac ttactgaaaa aatttaacatc tcttgctaaag ctggagctc gtcgacggat 7920  
 cgaattccctg cagatcggtt aaacatttgg caataaaagtt tcttaagatt gaatccgtt 7980  
 gcccggcttg cgatgattat catataattt ctgttgaattt acggttaagca tggtaataatt 8040  
 aacatgtat gcatgacgat atttatgaga tgggtttttt tgatttagat cccgcaatta 8100  
 tacatttaat acgcatataga aaacaaaata tagcgcgc当地 actaggataa attatgcgc 8160  
 gcggtgtcat ctatgttact agatctctag aactagtggta tctgcttagcc ctgcaggaaa 8220  
 tttaccgggt cccggggccgc cagcatggcc gtatccgcaa tggtaattttt agttgtctaa 8280  
 ggcgtcaattt gtttacacca caatatatcc tgccaccagc cagccaaacag cttcccgacc 8340  
 ggcagctcg cacaatca ccactcgata caggcagccc atcagaatattt attctcatgt 8400  
 ttgacagctt atcatcgact gcacgggtca ccaatgtttc tggcgtcagg cagccatcg 8460  
 aagctgttgtt atggctgtgc aggtgtaaa tcaactgcata attcggtgtc tggtaataattt 8520  
 actcccggtt tggataatgt ttttgcgc当地 gacatcataaa cgggttctggc aaatattctg 8580  
 aaatgagctg ttgacaattt atcatcggtt cgtataatgtt gtggaaattgtt gagcggataa 8640  
 caatttcaca cagggaaacag accatgaggg aagcgggtat cggccaaatgta tcgactcaac 8700  
 tattcagaggt agttggcgcc atcgagcgcc atctcgaaacc gacgttgc当地 ggcgttacatt 8760  
 tgtacggctc cgcagttggat ggcggcctga agccacacag tgatattgtt ttgctggta 8820  
 cgggtgaccgt aaggcttgat gaaacaacgc ggcggcgtt gatcaacgc ctttggaaa 8880  
 cttcggcttc ccctggagag agcgagattc tccgcgtgtt agaagtcacc attgttgc当地 8940  
 acgacgacat cattccgtgg cgttatccag ctaagcgc当地 actgcaattt ggagaatggc 9000  
 agcgaatga cattcttgc当地 ggtatcttgc agccagccac gatcgacatt gatctggcta 9060  
 tcttgctgac aaaagcaaga gaacatagcg ttgccttggtt aggtccagcg gcccggaaac 9120  
 tctttgatcc ggttccctgaa caggatctat ttgaggcgtt aaatgaaacc ttaacgctat 9180  
 ggaactcgcc gcccggactgg gctggcgatg agcggaaatgtt agtgcttacg ttgtcccgca 9240  
 tttggatcag cgcagtaacc ggcggaaatcg cggccggaaatggta tggcgtgtcc gactgggca 9300  
 tggagcgcctt gcccggcccg tatcagcccg tcaacttgc当地 agctaggcag gcttattttt 9360  
 gacaagaaga tggcttggcc tggcgc当地 agtggatggta agaattttt cactacgtg 9420  
 aaggcggat caccatggta gtcggcaaat aaagctctag tggatccccg agaatacgcc 9480  
 gtgacgggtcg caaaccatcc ggccgggtac aaatcgccg ggcgttgggtt gatgacctgg 9540  
 tggagaagttt gaaggccggc caggccggcc agcggcaacg catcgaggca gaagcaccggc 9600

ccggtaatc gtggcaagcg gccgctgatc gaatccgaa agaatcccgg caaccgcgg 9660  
 cagccgtgc ggcgtcgatt aggaagccgc ccaaggcga cgagcaaccā gatTTTtcg 9720  
 ttccgatgt ctatgacgtg ggcaccccgat atagtcgcag catcatggac gtggccgtt 9780  
 tccgtctgtc gaagcgtgac cgacgagctg gcgaggatcgat cctgctacgag cttccagacg 9840  
 ggcacgtaga ggTTTCAGCA gggccggccg gcatggccag tggatggat tacgacctgg 9900  
 tactgatggc ggTTTCCAT ctaaccgaat ccatgaacccg ataccggaa gggaaaggag 9960  
 acaagcccgcc cgccgtgtt cgtcccacacg ttgcggacgt actcaagtcc tgccggcag 10020  
 ccgatggcgg aaagcagaaa gacgacctgg tagaaacctg cattcggat aacaccacgc 10080  
 acgttgcatt gcagcgtacg aagaaggcca agaacgcggc cctggatcgat gtatccgagg 10140  
 gtgaaggcctt gattagccgc tacaagatcg taāagagcga aaccggggcg 10200  
 tcgagatcgat gctactgtat tgatgtacc gcgagatcac agaaggcag aaccggacg 10260  
 tgctgacggat tcaccccgat tacttttga tcgatcccgg catcgccgt tttctctacc 10320  
 gcctggcaccg ccgcggccgca ggcaggcag aagccagatg gttgttcaag acgatctacg 10380  
 aacgcagtgg cagccccggaa gagttcaaga agttctgtt caccgtgcgc aagctgatcg 10440  
 ggtcaaatgaa cctgccccggag tagtattga aggaggaggc gggcaggct gggccgatcc 10500  
 tagtcatcgat ctaccgcaac ctgatcgagg gcgaagcatc cgccgggttcc taatgtacgg 10560  
 agcagatgct agggcaaatt gccttagcag gggaaaaagg tcgaaaaggat ctcttcctg 10620  
 tggatagcac gtacattggg aacccaaagc cgtacattgg gaaccggaaac ccgtacattg 10680  
 ggaacccaaa ggcgtacatt gggacccggat cacacatgtat agtactgtat ataaaagaga 10740  
 aaaaaggcga ttTTTCCGC taaaactctt taaaacttat taaaaci: taaaaccgc 10800  
 tggctgtgc ataactgtct ggcagcgc aagccgaa gctgaaaaaa ggcctaccc 10860  
 ttcggtcgatc gegctcccta cggccggccg ctgcgtcg gcctatcgatc ggcgttgcc 10920  
 gctaaaaat ggctggcta cggccaggca atctaccagg ggcgggacaa ggcgcgcgt 10980  
 cgccactcgat cggccggccgat tgaggctcgat ctcgtgaaga aggtgttgcgactcatacc 11040  
 aggccctgaat cggcccatca tccagccaga aagtggggaa gccacgggtt atgagagctt 11100  
 tggttaggt ggaccagttt gtagtttga acttttgcgatc tgccacggaa cggctgcgt 11160  
 tgctggaaatg atgcgtgatc tgatcttca actcagaaaa agtgcattt attcaacaaa 11220  
 gcccgcgtcc cgtcaagtca gctaatgcgt ctgcgcgtt tacaaccaat taaccaattc 11280  
 tgattagaaaa aactcatcgat gcatcaaatg aaactgcaat ttattcatat caggattatc 11340  
 aataccatat ttggaaaaaa gcccgttctg taatgaagga gaaaactcac cgaggcagtt 11400  
 ccataggatg gcaagatcct ggtatcggtc tgcatcgatc actcgatccaa catcaataca 11460  
 acctattat ttcccctcgat caaaataag gttatcaatg gagaatcacat ctaggtgac 11520  
 gactgaatcc ggtgagaatg gcaaaagctc tgcatcaatg aatcgccaa cgcgcgggaa 11580  
 gagggcggtt gctgttggg cgtcttcccg ctgcgtcgatc cactgactcg ctgcgtcg 11640  
 tcgatcgatc gcccgcgcgat gtagtgcgtc actcaaaaggc ggtatcggatc ttatccacag 11700  
 aatcaggggaa taacgcagga aagaacatgt gagcaaaaagg ccagcaaaaagg gccaggaacc 11760  
 gtaaaaaaggc cgcgttgctg gcttttccat ataggctccg ccccccgtac gacatcaca 11820  
 aaaatcgacg ctcaagtca ggtggcgaa acccgacagg actataaaga taccaggcgt 11880  
 ttccccctgg aagctccctc gtgcgtctc ctgttccgac cctggcgatc accggatacc 11940  
 tgtccgcctt tcccccctcgat ggaagcgtgg cgctttctca atgctcacgc tggatgtatc 12000  
 tcagttcgatc gtaggtcgatc cgctccaaatc tggctgtgt gacgaaacc cccgttcagc 12060  
 cccggcgatc cgccttatcc ggtaaatcgtc gtcttgcgtt caacccggatc agacacgact 12120  
 tatcgccact ggcagcagcc actggtaaca ggatttagcag agcgaggat gtaggcgggt 12180  
 ctacagatgtt ctgttgcgtt gttttccat acggctacac tagaaggaca gtatggatc 12240  
 tctgcgtct gctgaagcca gttacccatc gaaaaagatg tggatgtatc tgatccggca 12300  
 aacaaaccac cgctggatc ggtgggtttt ttgttgcac gacgacgatc acgcgcagaa 12360  
 aaaaaggatc tcaagaatg cctttgtatc ttctacggg gtcgtacgtc cagtgaaacg 12420  
 aaaaactcactc ttaaggatg ttggatcgatc gattatcaaa aaggatcttc acctagatcc 12480  
 ttgttgcgtt gatattatc ctgtgggtgg catgcacata caaatggacg aacggataaa 12540  
 ccttttcacg ccctttttaaa tatccgatca ttctatcaaa cgctttttc tcttaggttt 12600  
 acccgccaaat atatccgtc aaacactgtat agttttaact gaaaggccggaa aacgacaatc 12660  
 tgatcatgatc gggagaatc agggagtcac gttatgaccc cccggatc ggcggacaa 12720  
 gccgttttac gtttggact gacagaaccc caacgctgca ggaatt 12766

<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1598

<400> 26  
catccatgg atccaatggc cacgaattaa agctatcacg tc

42

<210> 27  
<211> 44  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: ZUP1590

<400> 27  
acgcgtcgac cgccggattca aacgattatt aattacgata aaag

44

<210> 28  
<211> 11461  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: pZU634

<220>  
<221> promoter  
<222> (55)..(1786)  
<223> ubiquitin3 promoter plus leader intron

<220>  
<221> misc\_feature  
<222> (1790)..(2574)  
<223> PVY nt CP region

<220>  
<221> intron  
<222> (2595)..(3036)  
<223> actin2 intronL

<220>  
<221> misc\_feature  
<222> Complement((3057)..(3847))  
<223> PVY nt CP region

<220>  
<221> terminator  
<222> (3855)..(4124)  
<223> NOS terminator

<220>  
<221> promoter  
<222> (4193)..(5364)  
<223> SMAS promoter

<220>  
<221> gene  
<222> (5386)..(6561)  
<223> phosphomannose isomerase A coding sequence

<220>  
<221> terminator  
<222> (6623)..(6897)  
<223> nopaline synthase terminator

<220>  
<221> misc\_feature  
<222> (6949)..(7080)  
<223> nopaline left border fragment

<220>  
<221> gene  
<222> (7359)..(8147)  
<223> spectinomycin (aadA) coding sequence

<220>  
<221> misc\_structure  
<222> (8157)..(10244)  
<223> pVS1 ORI

<220>  
<221> misc\_structure  
<222> (10245)..(11179)  
<223> pUC19 ORI

<220>  
<221> misc\_feature  
<222> (11195)..(11450)  
<223> nopaline right border region

<220>  
<221> stem\_loop  
<222> (1790)..(3847)  
<223> PVY inverted repeat region

<400> 28  
ggccgcagcg gccatttaaa tcaattgggc ggcggaaatt cgagctcggt acccgtaaccg 60  
gatttggagc caagtctcat aaacgccatt gtggaaagaaa gtcttgagggt ggtggtaatg 120  
taacagagta gtaagaacag agaagagaga gagtgtgaga tacatgaatt gtcgggcaac 180  
aaaaatcctg aacatcttat tttagcaaag agaaagagtt ccgagtcgtt agcagaagag 240  
tgaggagaaa tttaagctct tgacttggt aattgttccg cctcttgaat acttcttcaa 300  
tcctcatata ttcttcctt atgttacctg aaaaccggca ttatctcg cgggtttatt 360  
ccgggttcaac atttttttt ttttgagttt ttatctggc ttataaacgc aggctgaaa 420  
taaattcaag gcccactgt tttttttt aagaagtgc tgtaaaaaaa aaaaaaagg 480  
aattaacaac aacaacaaaa aaagataaaag aaaataataa caattacttt aattgttagac 540  
aaaaaaaaaca tagattttat catgaaaaaaaaa agagaaaaaga aataaaaaact tggatcaaaa 600

aaaaaaaacat acagatcc tcattttaa cttttcttaa aaatttaggtc ctttttccca 660  
acaatttaggt ttagagtttt ggaattaaac caaaaagatt gttctaaaaa atactcaaat 720  
ttggtagata agttcccta tttaattag tcaatggtag atacttttt ttctttctt 780  
tattagagta gattagaatc ttatgccca agtttgata aattaaatca agaagataaa 840  
ctatcataat caacatgaaa taaaagaaa aatctcatat atagtattag tattcttat 900  
atatattatg attgcttatt cttaatgggt tgggttaacc aagacatagt cttaatggaa 960  
agaatctttt ttgaacttt tccttattga ttaaattctt ctatagaaaa gaaagaaaatt 1020  
atttgaggaa aagtatatac aaaaagaaaa atagaaaaat gtcagtgaag cagatgtaat 1080  
ggatgaccta atccaaccac caccatagga tggttctact tgagtccgc ttttaaaaac 1140  
gcacgggtgga aaatatgaca cgtatcatat gattccctcc tttagttcg tgataataat 1200  
cctcaactga tatcttcctt ttttgcatt ggctaaagat atttattctt cattaataga 1260  
aaagacgggtt ttgggctttt gggttgcgtt ataaaagaaga ctttcgtgtg gaagataata 1320  
attcatccctt tgcgtttttt ctgactttc aatctctccc aaaggctaaa gcgcattctg 1380  
caaattcttc gcgactctt cttaaaggtt atatttctg attcttttgc ttttgcattc 1440  
gtatctgatc tccaaattttt gttatgtggat ttattgaatc ttttgcattaa attgcctttt 1500  
acaatattgt tcgttgcgc aatccagttt ctaaatttttgc tcctgattac taagatatcg 1560  
attcgtagt tttacatctg tgtaatttttgc tgcttgattt tgaaatttagg attttcaagg 1620  
acgatctattt caattttttgc gttttcttttgc ttcgattctc tctgttttag gtttctttagt 1680  
tttagatccg tttctcttttgc gtgttgcattt gatttcttgc acggcttttgc atttgggtata 1740  
tggtcgctga ttgggttttgc ctgtttttttgc tggtttttttgc caggtggggg atccaatggc 1800  
cacgaattaa agctatcacg tccaaaatgaa gaatgcggaa gagtaagggt gcaactgtac 1860  
taaatttggaa acacctactc gagtgcgc cacagcaat tgaaatctca aataactcgag 1920  
caactcaatc acagtttgc acatggatg aagcagtaca acttgcatatc gacataggag 1980  
aaactgaaat gccaactgtg atgaatgggc ttatggtttgc gtgcatttgc aatggaaacct 2040  
cgccaaatataat caatggatgtt tgggttttgc tggtttttttgc tgaacaatgc gaataaccac 2100  
tgaaatccaat cggttgcattt gcaaaaaccaat cacttaggca aatcatggca catttctca 2160  
atgttgcaga agcgatata gaaatgcgc acaaaaagga accatataatgc ccacgatatgc 2220  
gttttagttcg taatctgcgc gatggatgtt tggctcgatc tgcttttgc ttttgcatttgc 2280  
ttacatcactc tacaccatgc aggcttagatg aggccacatc tcaatgcatttgc gccgcagctt 2340  
taaaatcactc tcaatctca cttttgcatttgc tggttgcatttgc cattatgcatttgc 2400  
acacagagag gcacaccacc gaggatgttt ctccaaatgtt gcataactcta ctggagtgc 2460  
agaacatgtg attgtatgtt ctcccttgcatttgc gatataatgc tattttatgtt tgactgtatgt 2520  
attttgcattt ttcctgtactt acttttgcatttgc taattatataatgc tggttgcatttgc 2580  
tctttcttgc caaggtaata ggaacttttgc tggttgcatttgc tattttgcatttgc 2640  
tggtttctca atttccttgc gatcttgcatttgc tggttgcatttgc tggatctgtg aacccacttgc 2700  
aaatcttttgc gttttacttag aatctgcatttgc agttgcatttgc tcaatgcatttgc 2760  
taccagaattt tggcttgcatttgc ttgttgcatttgc gatccatgtt catgttacatc 2820  
ttgtatgtt gaatttgcatttgc ctgttgcatttgc tggttgcatttgc tggatctgtt 2880  
gttagattgtt atctgcatttgc tggttgcatttgc agatgttgcatttgc tggatctgtt 2940  
ctttagattt tggatctgttgc tcaatgcatttgc agaaatgttgcatttgc ttttgcatttgc 3000  
atttgactgtt attgttgcatttgc ttgttgcatttgc ttgttgcatttgc tggatctgtt 3060  
ggatcttgcatttgc gatcttgcatttgc tggatctgttgcatttgc tggatctgtt 3120  
caaaatataat ttttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3180  
agtagatgtt gcaatgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3240  
tgtgtacttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3300  
gccttcatttgc gatcttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3360  
aagtcaaaat gatcttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3420  
ggatcttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3480  
tgtgtacttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3540  
tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3600  
ttttcaatgc accaaatccat tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3660  
tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3720  
tttgagattt caatttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3780  
gcacccatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3840  
atccatgggtt gatcttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3900  
tccatgggtt gatcttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc tggatctgttgcatttgc 3960

aataattaac atgtaatgca tgacgttatt tatgagatgg gtttttatga ttagagtccc 4020  
 gcaattatac attaatacg cgatagaaaa caaaatatag cgccaaacct aggataaaatt 4080  
 atcgcgcgct gtgtcatcta tgtactaga tctctagaaa gcttcgtacg ttaattaatt 4140  
 cgaatccgga gcggccgcag ggctagcatc gatggtaccg agctcgagac tatacaggcc 4200  
 aaattcgctc ttagccgtac aatattactc accggtgcca tgccccccat cgtaggtgaa 4260  
 ggtggaaatt aatgatccat cttgagacca caggcccaca acagctacca gtttcctcaa 4320  
 gggtccacca aaaacgtaaag cgcttacgta catggtcgat aagaaaaggc aatttgtaga 4380  
 ttttaacatc caacgtcgct ttcaaggatc ccgaattcca agcttggaaat tcgggatcct 4440  
 acaggccaaa ttgcgtctta gccgtacaat attactcacc ggtgcgtgc ccccccattcg 4500  
 aggtgaaggt gggaaattaaat gatccatctt gagggccacag gcccacaaca gctaccagt 4560  
 tcttcaaggg tccaccaaaa acgtaaagcgc ttacgtacat ggtcgataag aaaaggcaat 4620  
 ttgttagatgt taacatccaa cgtcgtttc agggatcccg aatttcaagc ttggaaattcg 4680  
 ggatccctaca ggccaaattc gctcttagcc gtacaatatt actcaccggc gcgatcccc 4740  
 catcgtaggt gaagggtgaa attaatgatc catttgaga ccacaggccc acaacagcta 4800  
 ccagtttccat caagggtcca cccaaaacgt aagcgcttac gtacatggc gataagaaaa 4860  
 - ggcattttgt agatgttaac atccaacgtc gcttcaggg atcccaattt ccaagcttgg 4920  
 gctgcaggc aatcccatgg cttttgaagc agctcaacat tgatctctt ctcgaggggag 4980  
 atttttcaaa tcagtgcgc aagacgtgacg taagtatccg agtcagttt tattttctta 5040  
 ctaatttggt cgtttatttc ggcgtgttagg acatggcaac cgggcctgaa ttgcggggt 5100  
 attctgtttc tatttcaact ttttcttgat ccgcagcattt aacgacttt tgaatagata 5160  
 cgctgacacg ccaagcctcg ctatcaaaa gtgtacccaa caacgcttta cagcaagaac 5220  
 ggaatgcgcg tgacgctcgc ggtgacgcca ttgcgtttt tcagaaatgg ataaatagcc 5280  
 ttgcttccta ttatatctt ccaaattacc aatacattac actagcatct gaatttcata 5340  
 accaatctcg atacacccaa tcgagatctg caggatccc cgatcatgca aaaactcatt 5400  
 aactcagtgc aaaactatgc ctggggcagc aaaacggcgt tgactgaact ttatggatg 5460  
 gaaaatccgt ccagccagcc gatggccgag ctgtggatgg ggcacatcc gaaaaggcgt 5520  
 tcacgagtgc agaatgcgcg cggagatatac gtttcaactgc gtatgtgat tgagagtgat 5580  
 aaatcgactc tgctcgaga ggccgttgcc aaacgcttt ggcgaactgccc tttctgttc 5640  
 aaagtattat ggcgcgacaca gccactctcc attcagggttcc atccaaacaa acacaattct 5700  
 gaaatcggtt ttgccaaga aatgcgcga ggtatcccgta tggatgccgc cgagcgtaac 5760  
 tataaagatc ctaaccacaa gccggagctg gttttgcgc tgacgcctt cttgcgtatg 5820  
 aacgcgtttc gtgaattttc cgagattgtc tccctactcc agccggtcgc aggtgcacat 5880  
 ccggcgattt ctcactttt acaacagcct gatgcgaac gtttaagcga actgttcgccc 5940  
 agcctgttga atatgcaggg tgaagaaaaa tcccgccgc tggcgatttt aaaatcgccc 6000  
 ctcgatagcc agcagggtga accgtggcaa acgattcgat taatttctga attttacccg 6060  
 gaagacagcg gtctgttctc cccgttattt ctgaatgtgg tggaaatttggaa ccctggcgaa 6120  
 gcgatgttcc tggtcgctga aacaccgcac gcttacctgc aaggcgccgc gctggaaagt 6180  
 atggcaaaact ccgataacgt gctgcgtgc ggtctgacgc ctaaatacat tgatattccg 6240  
 gaactggttt ccaatgtgaa attcgaagcc aaaccggcta accagtgtt gacccagccg 6300  
 gtgaaacaag gtgcagaact ggacttcccg attccagttt atgatatttgc ttctcgctg 6360  
 catgaccttta gtgataaaga aaccaccatt agccagcaga tgccgcctt tttgttctgc 6420  
 gtcgaaggcg atgcaacgtt gtggaaagggt tctcagcagt tacagctta accgggtgaa 6480  
 tcagcgttta ttggcccaa cgaatcacccg gtgactgtca aaggccacgg ccgtttagcg 6540  
 cgtgtttaca acaagctgtt aagacttact gaaaaatttta acatctctt ctaagctggg 6600  
 agctcgtcgat cggatcgat tctcgatccat cgttcaaaata tttggcaata aagtttctta 6660  
 agattgaatc ctgttgcggg tcttgcgtatg attatcatat aatttctgtt gaattacgtt 6720  
 aagcatgtta taattaacat gtaatgcgtt acgttattttt tgagatgggt ttttattgatt 6780  
 agagtcccgcc aattatacat ttaataacgcg atagaaaaaca aaatatacg gcaaaacttag 6840  
 gataaattat cgcgcgcgt gtcatctatg ttacttagt tctagaacta gtggatctgc 6900  
 tagccctgca gggaaatttac cgtgtcccg gcccgcagca tggccgtatc cgcaatgtgt 6960  
 tattaagttt tctaagcgat aatttgcgtt caccacaata tatccctgcca ccagccagcc 7020  
 aacagctccc cggccggcag ctccggcacaat aatcaccact cgatcagggc agcccatcag 7080  
 aattaattctt catgtttgac agcttattcat cgactgcacg gtgcaccaat gcttctggcg 7140  
 tcaggcagcc atcggaaagct gtggatggc tggcagggtc gtaaatact gctataattcg 7200  
 tggcgtctcaa ggcgcactcc cgttctggat aatgtttttt gcccgcacat cataacgggtt 7260  
 ctggccaaata ttctgaaatg agctgttgc aattaatcat cggtcgat aatgtgtgga 7320

attgtgagcg gataacaatt tcacacagga aacagaccat gagggaaagcg gtgatcgccg 7380  
 aagtatcgac tcaactatca gaggtatgg cgctcatcg ggcgcacatctc gaaccgacgt 7440  
 tgctggccgt acatttgtac ggctccgcag tggatggcgg cctgaagcca cacagtata 7500  
 ttgatgtgc ggttacggtg accctaaggc ttgatgaaac aacgcggcga gctttgatca 7560  
 acgacccccc gaaaaacttcg gcttccccgt gagagagcga gatttccgc gctgtagaag 7620  
 tcaccattgt tggcacac gacatcattc cgtggcgta tccagctaag cgcgaactgc 7680  
 aatttgaga atggcagcgc aatgacattc ttgcaggat cttcgagcca gccacgatcg 7740  
 acattgatct ggctatctt ctgacaaaag caagagaaca tagcgttgc ttggtaggtc 7800  
 cagcggcggg ggaactttt gatccgggtc ctgaaacaggc tctatttgag ggcctaattg 7860  
 aaaccttaac gctatggaa tcgcccggc actgggttgg cgatgagcga aatgtatgtc 7920  
 ttacgttgc cccgattttg tacagcgcag taacccggcaa aatcgcccg aaggatgtcg 7980  
 ctggcactg ggcaatggag cgccctggc cccagatata gcccgtata cttgaagcta 8040  
 ggcaggctt tcttggacaa gaagatcgct tggcctcg cgcagatcg ttggagaat 8100  
 ttgttcaacta cgtgaaaggc gagatcaca aggtatgtgg caaataaaagc tctatgtggat 8160  
 ccccgaggaa tcggcgtgac ggtcgcaaac catccggccc ggtacaaaatc ggcgcggcgc 8220  
 tgggtgatga cctggtgag aagtgaagg ccgcgcaggc cgcccagcgg caacgcacatcg 8280  
 aggccagaaggc acgccccggt gaatcggtc aagcggccgc tgatcgatc cgccaaagaat 8340  
 cccggcaacc gccggcagcc ggtgcggcgt cgatttaggaa gccgccaag ggcgacgagc 8400  
 aaccagattt ttctgttccg atgcctatcg acgtgggcac ccgcgatagt cgccatcgatca 8460  
 tggacgtggc cgttttccgt ctgtcgaaagc gtgaccgcac agctggcgg agtgcgttgc 8520  
 acgagcttcc agacgggcac gttaggggtt cagcaggggcc ggcgcgcattt gccagtgtgt 8580  
 gggattacga cctggtaactg atggcggtt cccatctaacc cgaatccatg aaccgatacc 8640  
 gggaaaggaa gggagacaag cccggcccg tggccgtcc acacgttgc gacgtactca 8700  
 agttctgcgc gcgagccat ggcgaaagc agaaagacga cctggtagaa acctgcattt 8760  
 ggttaaacac cacgcacgtt gccatgcagc gtacgaagaa ggccaagaac ggccgcctgg 8820  
 tgacggtatac cgagggtgaa gccttgatta gcccgtacaa gatcgtaaag agcggaaaccc 8880  
 ggccggccgga gtacatcgag atcgagctag ctgattggat gtaccgcgg atcacagaag 8940  
 gcaagaaccc ggacgtgtc acggttccacc ccgattactt ttgtatcgat cccggcatcg 9000  
 gccgtttctt ctaccgcctg gcacccggc cccgaggcaaa ggcagaagcc agatgggtgt 9060  
 tcaagacgat ctacgaacgc agtggcagcg ccggagagtt caagaagttc tggccatccg 9120  
 tgcgcagact gatcggttca aatgacctgc cggagatcgaa ttgttgcggag gaggccggc 9180  
 aggctggccc gatcctagtc atgcgttacc gcaacctgtat cgagggcgg gcatccgc 9240  
 gttcttaatg tacggagcag atgcgttggc aaatttgcctt agcaggggaa aaaggtcgaa 9300  
 aaggctcttt tccctgtgat agcacgtaca ttggggacccc aaagccgtac attgggaaacc 9360  
 ggaacccgta cattggaaac cccaaagccgt acattgggaa ccggccatcac atgtaaatgt 9420  
 ctgatataaa agagaaaaaa ggcgatttt ccgcctaaaaa ctctttaaaaa ctattaaaaa 9480  
 ctctttaaaac ccgcctggcc tgcataacc tgcgtggcca ggcacagcc gaagagctgc 9540  
 aaaaagcgc tacccttcgg tcgctgcgtt ccctacggccc ccggccatcg cgtccggctt 9600  
 tcgcggccgc tggccgtca aaaatggctg ccgtacggcc aggcaatcta ccaggccgc 9660  
 gacaaggccg gccgtcgcca ctcgaccggc ggcgttgagg tctgcctcgta gaagaagggtg 9720  
 ttgcgtactc ataccagcc tgaatcgccc catcatccag ccagaaatgt agggagccac 9780  
 ggttgcgttgc agctttttt tagtggacc agttggat tttgtactt tgcgttgc 9840  
 cggaaacggc tgcgttgc ggaagatgcg tgatctgtat cttcaactca gcaaaatgtt 9900  
 gatttattca acaaaggccg cgtcccgta agtcagcgtt atgcgttgc agtgttacaa 9960  
 ccaattaacc aattcttattt agaaaaactc atcgagcatc aaatgaaaact gcaattttt 10020  
 catatcgaga ttatcaatac catattttgg aaaaaggccgt ttctgtatcg aaggagaaaa 10080  
 ctcaccggagg cagttccata ggtggcaag atcctgtat cggctcgatc ttccgactcg 10140  
 tccaaacatca atacaaccata ttaattttccctt ctcgtcaaaa ataaggatcgat caatgtgagaa 10200  
 atcaccatga tgcgtactg aatccggtaa gatggcaaa agtctgtatcg taatgtatcg 10260  
 gccaacgcgc gggggagggc ggttgcgtt tggccgtcc ttccgcttcc tgcgtactcg 10320  
 actcgctgcg ctcggctgtt cggctcgcc ggcgttgatc agtctgtatcg aaggccgtt 10380  
 tacggttatc cacagaatca ggggataacg cagggaaagaa catgtgagca aaaggccagc 10440  
 aaaaaggccag gaaccgtaaa aaggccgtt tgctggcgat tttccatagg ctccggcccc 10500  
 ctgacgagca tcacaaaaat cgacgctaa gtcagagggtt ggcggaaaccgg acaggactat 10560  
 aaagatacc ggcgtttccctt ctcgtcaagc ccctcgatcg ctctctgtt ccgaccctgc 10620  
 cgcttaccgg atacctgtcc gccttctcc ctgcggaaag cgtggcgatc tctcaatgtt 10680

cacgctgtag gtatctcagt tcggtgttagg tcgttcgcctc caagctggc tttgtgcacg 10740  
aaccccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 10800  
cgtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 10860  
ggtatgttagg cggtgctaca gagttcttga agtggtgcc taactacggc tacactagaa 10920  
ggacagtatt tggtatctgc gctctgctga agccagttac cttcgaaaaa agagttggta 10980  
gctcttgcata cggcaaaaca accaccgctg gttaggggtt ttttttggta tgcaagcagc 11040  
agattacgca cagaaaaaaa ggatctcaag aagatcctt gatctttct acgggggtctg 11100  
acgctcagtg gaacgaaaaac tcacgttaag ggattttgtt catgagatta tcaaaaaggaa 11160  
tcttcaccta gatccttttgc atccggaaatt aattcctgtg gttggcatgc acatacaaatt 11220  
ggacgaacgg ataaaccttt tcacgcccctt ttaaatatcc gattattcta ataaacgctc 11280  
tttctctta ggtttacccg ccaatatatac ctgtcaaaaca ctgatagttt aaactgaagg 11340  
cgggaaacga caatctgatc atgagcggag aattaaggga gtcacgttat gaccccccggcc 11400  
gatgacgcgg gacaagccgt tttacgttttgaactgacag aaccgcaacg ctgcaggaat 11460  
t 11461

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/04117

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/11 C12N15/63 C12N15/82 A01N63/00 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N A01N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.        |
|------------|---|------------------------------|
| X          | <p>WATERHOUSE ET AL: "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, vol. 95, no. 95, November 1998 (1998-11), pages 13959-13964, XP002114472</p> <p>ISSN: 0027-8424</p> <p>the whole document</p> | 1-7, 23,<br>27, 28,<br>30-33 |
| Y          | —/—   | 10-13                        |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"g" document member of the same patent family

Date of the actual completion of the international search

4 September 2000

Date of mailing of the international search report

21/09/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3018

Authorized officer

Maddox, A

## INTERNATIONAL SEARCH REPORT

Int'l "onal Application No  
PCT/EP 00/04117

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                  |
|------------|--|--|
| X          | SIJEN TITIA ET AL: "RNA-mediated virus resistance: Role of repeated transgenes and delineation of targeted regions." PLANT CELL, vol. 8, no. 12, 1996, pages 2277-2294, XP002146482 ISSN: 1040-4651 page 2284, left-hand column ---  | 1-6,<br>10-13,<br>27,30-33             |
| Y          | ---  | 10-13                                  |
| P,X        | WO 99 53050 A (WANG MING BO ;COMMW SCIENT IND RES ORG (AU); GRAHAM MICHAEL WAYNE) 21 October 1999 (1999-10-21) the whole document ---  | 1-7,23,<br>24,27,<br>28,30-33          |
| P,X        | WO 99 49029 A (GENE AUSTRALIA LIMITED AG ;GRAHAM MICHAEL WAYNE (AU); RICE ROBERT) 30 September 1999 (1999-09-30) the whole document ---  | 1-6,8,<br>10-13,<br>18,27,<br>28,30-33 |
| P,X        | WO 99 32619 A (CARNEGIE INST OF WASHINGTON ;MONTGOMERY MARY K (US); FIRE ANDREW ()) 1 July 1999 (1999-07-01) claims 1,5 ---  | 1,27                                   |
| A          | BAULCOMBE D: "Mechanisms of pathogen-dereived resistance to viruses in transgenic plants" PLANT CELL,US,AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, vol. 8, no. 10, 1 October 1996 (1996-10-01), pages 1833-1844, XP002095878 ISSN: 1040-4651 the whole document --- | 1-33                                   |
| A          | WO 98 36083 A (ANGELL SUSAN MARY ;BAULCOMBE DAVID CHARLES (GB); PLANT BIOSCIENCE) 20 August 1998 (1998-08-20) the whole document ---   | 1-33                                   |
| A          | WO 99 15682 A (LEDERER CARSTEN WERNER ;BAULCOMBE DAVID CHARLES (GB); VOINNET OLIV) 1 April 1999 (1999-04-01) the whole document ---  | 1-33                                   |
| A          | WO 98 37223 A (CORNELL RES FOUNDATION INC) 27 August 1998 (1998-08-27) the whole document ---  | 1-33                                   |
| A          | WO 98 53083 A (LOWE ALEXANDRA LOUISE ;GRIERSON DONALD (GB); ZENECA LTD (GB); HAMI) 26 November 1998 (1998-11-26) the whole document ---  | 10-13                                  |
|            |  | -/-                                    |

## INTERNATIONAL SEARCH REPORT

Int'l'nal Application No  
PCT/EP 00/04117

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | MONTGOMERY M K ET AL: "Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression" TRENDS IN GENETICS, NL, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 255-258, XP004124680 ISSN: 0168-9525 the whole document<br>--- | 1-33                  |
| A          | GRANT SARAH R: "Dissecting the mechanisms of posttranscriptional gene silencing: Divide and conquer." CELL, vol. 96, no. 3, 5 February 1999 (1999-02-05), pages 303-306, XP002146483 ISSN: 0092-8674 the whole document<br>---   | 1-33                  |
| A          | WO 90 14090 A (HEM RES INC)<br>29 November 1990 (1990-11-29)<br>page 5<br>---  | 25, 26                |
| P, A       | WO 99 61631 A (NOVARTIS ERFINDUNGEN VERWALTUNG; NOVARTIS AG (CH); HEIFETZ PETER BE) 2 December 1999 (1999-12-02)<br>the whole document<br>---  | 1-33                  |
| E          | WO 00 44914 A (FARRELL MICHAEL J ; LI YIN XIONG (US); KIRBY MARGARET L (US); MEDIC) 3 August 2000 (2000-08-03)<br>claims 1,6,7<br>-----  | 1, 27                 |

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Int'l Application No

PCT/EP 00/04117

| Patent document cited in search report |   | Publication date |                      | Patent family member(s)                          |  | Publication date                                     |
|--|---|------------------|----------------------|--|--|--|
| WO 9953050                             | A | 21-10-1999       | AU                   | 2951499 A  |  | 01-11-1999   |
| WO 9949029                             | A | 30-09-1999       |                      | NONE   |  |  |
| WO 9932619                             | A | 01-07-1999       | AU                   | 1938099 A  |  | 12-07-1999   |
| WO 9836083                             | A | 20-08-1998       | AU<br>EP             | 6001698 A<br>0970228 A                           |  | 08-09-1998<br>12-01-2000                             |
| WO 9915682                             | A | 01-04-1999       | AU<br>EP<br>AU<br>EP | 9175198 A<br>1017831 A<br>6001698 A<br>0970228 A |  | 12-04-1999<br>12-07-2000<br>08-09-1998<br>12-01-2000 |
| WO 9837223                             | A | 27-08-1998       | AU<br>CN<br>EP       | 6657198 A<br>1252102 T<br>0970237 A              |  | 09-09-1998<br>03-05-2000<br>12-01-2000               |
| WO 9853083                             | A | 26-11-1998       | AU<br>EP             | 7444298 A<br>0983370 A                           |  | 11-12-1998<br>08-03-2000                             |
| WO 9014090                             | A | 29-11-1990       | EP<br>JP             | 0473576 A<br>4507083 T                           |  | 11-03-1992<br>10-12-1992                             |
| WO 9961631                             | A | 02-12-1999       | AU                   | 4368399 A  |  | 13-12-1999   |
| WO 0044914                             | A | 03-08-2000       |                      | NONE   |  |  |

